Rare Cancer News & Clinical Trials

Unread items (100)

1 2 3 ... 58

lobular breast carcinoma in situ child sexual abuse poems - French Tribune

Posted: August 12th, 2018, 8:16pm GMT

lobular breast carcinoma in situ child sexual abuse poems
French Tribune
The condition is a laboratory diagnosis and refers to unusual cells in the lobules of the breast.The lobules and acini of the terminal duct-lobular unit lobular breast carcinoma in situ child sexual abuse poems tdlu , the basic functional unit of the ...

Acinic Cell Carcinoma - News-Medical.net

Posted: June 20th, 2018, 11:23pm GMT

News-Medical.net

Acinic Cell Carcinoma
News-Medical.net
Acinic cell carcinoma is a rare cancer of the salivary glands that originates from the parotid gland. It is a low-grade salivary neoplasm that constitutes about 5% to 17% of cases involving salivary gland malignancies. In comparison with other salivary ...

Hydrogel microenvironments for cancer spheroid growth and drug screening - Science Advances

Posted: April 27th, 2018, 4:09pm GMT

Hydrogel microenvironments for cancer spheroid growth and drug screening
Science Advances
Biomimetic hydrogel scaffolds for MCS growth offer a broad spectrum of biophysical and biochemical cues that help to recapitulate the behavior of natural extracellular matrix, essential for regulating cancer cell behavior. This perspective highlights ...

and more »

ER-phagy to alleviate stress - Science

Posted: February 6th, 2018, 5:14pm GMT

Science

ER-phagy to alleviate stress
Science
Smith et al. found that the ER-resident protein cell cycle progression gene 1 (CCPG1) trafficked between the ER and autophagosomes in cultured lung cancer cells and bound to both FIP200 and ATG8, proteins that are recruited to sites of autophagosome ...

Permalink for '[Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].'

[Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].

Fetched: August 17th, 2018, 5:00am GMT

[Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].

Zhonghua Bing Li Xue Za Zhi. 2018 Aug 08;47(8):574-579

Authors: Zhao YN, Wang XT, Xia QY, Wang GP, Sun SY, Zhao LF, Zhou XJ, Rao Q

Abstract
Objective: To study the clinicopathologic features, immunophenotype, characteristic FISH pattern and prognosis of renal cell carcinoma (RCC) associated with chromosome X inversion harboring gene fusions involving TFE3. Methods: Ten cases of NONO-TFE3 RCC and four cases of RBM10-TFE3 RCC were investigated at Nanjing Jinling Hospital from 2009 to 2016 by clinicopathological findings, immunohistochemistry, and genetic analysis. Results: Morphologically, the distinct pattern of secretory endometrioid subnuclear vacuolization was overlapped with clear cell papillary RCC, and often accompanied by sheets of epithelial cells in NONO-TFE3 RCC. Most cases of RBM10-TFE3 RCC presented with the biphasic feature that acinar, tubular and papillary patterns of epithelioid cells combined with sheets of small cells with "pseudorosette-like" architectures. In addition, cytoplasmic vacuolization, nuclear groove, and psammoma bodies were also observed. Immunohistochemically, all NONO-TFE3 RCC cases were immunoreactive for TFE3, CD10, RCC markers, and PAX8, and negative for CK7, Cathepsin K, Melan A, HMB45, Ksp-cadherin, vimentin, and CD117. All 4 cases of RBM10-TFE3 RCC showed moderate to strong immunoreactivity for TFE3, Cathepsin K, CD10, Ksp-cadherin, E-cadherin, P504s, RCC marker, PAX8, and vimentin but negative for TFEB, HMB45 and CK7. CKpan and Melan A were at least focally expressed. The antibody to Ki-67 showed labeling of 3%-8% (mean 5%). There were some expression discrepancies of immunochemistry between different histological patterns. PAX8, CKpan, P504s, and Ksp-cadherin were expressed in epithelioid areas but not in small-cell areas. Ki-67 labeling index of epithelioid areas was higher than that in small-cell areas. In molecular analysis, NONO-TFE3 fusion transcripts were identified in 6 patients. The fusion points were between exon 7 of NONO and exon 6 of TFE3 in 5 patients and between exon 9 of NONO and exon 5 of TFE3 in one patient. All 4 cases of RBM10-TFE3 RCC demonstrated to have RBM10-TFE3 fusion transcripts and the fusion points were between exon 5 of TFE3 and exon 17 of RBM10. Using TFE3 break-apart FISH assay, all 10 cases of NONO-TFE3 RCC showed characteristic patterns of equivocal split signals with a distance of nearly 2 signal diameters. All 4 cases of RBM10-TFE3 RCC showed colocalized or subtle split signals with a distance of <1 signal diameter, which was considered as negative results. Long-term follow-up was available for 7 patients of NONO-TFE3 RCC and 4 patients of RBM10-TFE3 RCC. All patients were alive with no evidence of disease. Conclusions: Two rare genotypes, NONO-TFE3 RCC and RBM10-TFE3 RCC, are reported in this study. Both of these two tumors show specific morphology and good prognosis, along with the positive TFE3 staining and the equivocal or false-negative TFE3 FISH results, which could be missed. PCR detection or next-generation sequencing can determine the genotype.

PMID: 30107660 [PubMed - in process]

Pancreatic Acinar Cell Carcinoma with Multiple Liver Metastases Effectively Treated by S-1 Chemotherapy.

Fetched: August 15th, 2018, 5:00am GMT

Pancreatic Acinar Cell Carcinoma with Multiple Liver Metastases Effectively Treated by S-1 Chemotherapy.

Intern Med. 2018 Aug 10;:

Authors: Yoshida N, Kanno A, Masamune A, Nabeshima T, Hongo S, Miura S, Takikawa T, Hamada S, Kikuta K, Kume K, Ueno M, Shimosegawa T

Abstract
A 79-year-old woman was referred for pancreatic tail cancer with multiple liver metastases. The pancreatic tail tumor was diagnosed as acinar cell carcinoma (ACC) histologically by endoscopic ultrasound-guided fine-needle aspiration. Because of multiple liver metastases, S-1 chemotherapy was administered, resulting in a partial response to chemotherapy one year later. After approximately three years, liver atrophy and esophageal varices developed. We suspected S-1 as the cause of the liver cirrhosis. S-1 cessation minimized ascites and improved the esophageal varices. Although S-1 can potentially treat ACC, we should be watchful for liver cirrhosis caused by its long-term administration.

PMID: 30101903 [PubMed - as supplied by publisher]

Pancreatic Mass in a Patient With an Increased Serum Level of IgG4.

Fetched: August 10th, 2018, 5:00am GMT

Pancreatic Mass in a Patient With an Increased Serum Level of IgG4.

Gastroenterology. 2018 08;155(2):269-270

Authors: Matsumori T, Shiokawa M, Kodama Y

PMID: 29410043 [PubMed - indexed for MEDLINE]

[Clinicopathologic and molecular genetic analysis of secretory carcinoma of salivary gland].

Fetched: August 9th, 2018, 5:00am GMT

[Clinicopathologic and molecular genetic analysis of secretory carcinoma of salivary gland].

Zhonghua Kou Qiang Yi Xue Za Zhi. 2018 Aug 09;53(8):533-538

Authors: Zhao M, Zhao DH, Cheng G, Yan YJ, Wang Z, He XL

Abstract
Objective: To investigate the clinicopathologic and molecular genetic features of secretory carcinoma of salivary gland (SCSG). Methods: Six cases of SCSG were collected from Zhejiang Provincial People's Hospital from January 2011 to March 2018. The clinical, histopathological and immunohistochemical features were analyzed and fluorescence in situ hybridization (FISH) was used to detect ETV6 gene rearrangement. Results: Four out of 6 tumors originated in the parotid gland and one of each in the minor salivary glands of soft palate and the buccal mucosa. Grossly, 4 cases were solid and 2 were partially cystic with maximum diameter ranging from 1.0 to 4.0 cm. Microscopically, 5 tumors showed typical features of low grade SCSG with tumor divided by thin fibrous septa into lobules composed of solid acinar, microcystic, follicular and papillary structures with abundant extracellular mucinous secretions. The tumor cells had cuolated or hobnail cytoplasm with low-grade nuclei and scarce mitoses. Perineural invasion was present in 1 case. The remaining tumor showed about 30% of the tumor areas with high-grade transformation characterized by proliferation of a distinct population of anaplastic cells arranged in irregular glandular, small nested and single cell patterns that were surrounded by desmoplastic stroma and invaded into surface mucosa with ulceration. Immunohistochemistry showed that all 6 tumors had diffuse and strong reactivities to S100 protein and cytokeratin 7, and 4 cases showed focal reactivity to gross cystic disease fluid protein 15 (GCDFP15), all were negative for discovered on gist 1 (DOG1), cytokeratin 20, p63 and calponin. High grade transformation cases were analysed, the high grade SCSG components showed a significantly increased Ki-67 index and cyclin D1 positive tumor cells compared to the conventional SCSG components. FISH analyses showed that 4 cases had ETV6 gene rearrangement. Eleven to seventy one months' follow-up showed no evidence of tumor recurrence nor metastasis. Conclusions: SCSG harbors characteristic genetic abnormalities with ETV6 gene rearrangement and typically shows a low grade morphology with occasionally, high grade transformation can be present.

PMID: 30078266 [PubMed - in process]

Acinic cell carcinoma of minor salivary glands - case report.

Fetched: August 9th, 2018, 5:00am GMT

Acinic cell carcinoma of minor salivary glands - case report.

Rom J Morphol Embryol. 2017;58(3):1003-1007

Authors: Buhaş CL, Roşca E, MuŢiu G, Venter AC, Buhaş BA, CouŢi R, Ciobanu CF, Roşca DM

Abstract
Salivary gland tumors have a high incidence (90%) within the parotid gland. The acinic cell carcinoma (ACC) represents only 1-3% of the salivary gland tumors, most frequently affecting the parotid. The minor salivary glands rarely develop ACC and when the ACC is localized in these glands, generally, it has a less aggressive evolution. The main criterion in the diagnostic of ACC is the histological examination with the regular Hematoxylin-Eosin (HE) staining and additionally Periodic Acid-Schiff (PAS) special staining. Immunohistochemical (IHC) examination confirms the origin of the tumor cells and the cellular proliferation index. Therapeutic management consists of surgical excision and radiotherapy. Left jugular tumor was the clinical diagnosis in the case we presented. The computed tomography (CT) examination revealed a voluminous expansive process of the left cheek. Surgery was performed with tumor resection and the skin defect was threatened. The histopathological (HP) and IHC exams have established the diagnosis of minor salivary glands adenocarcinoma with increased tumor proliferation index. The evolution was unfavorable to tumor recurrence in a short time of one year.

PMID: 29250681 [PubMed - indexed for MEDLINE]

Surgical resection of hepatic and rectal metastases of pancreatic acinar cell carcinoma (PACC): a case report.

Fetched: August 7th, 2018, 5:00am GMT

Surgical resection of hepatic and rectal metastases of pancreatic acinar cell carcinoma (PACC): a case report.

World J Surg Oncol. 2018 Aug 03;16(1):158

Authors: Ohara Y, Oda T, Enomoto T, Hisakura K, Akashi Y, Ogawa K, Owada Y, Domoto Y, Miyazaki Y, Shimomura O, Kurata M, Ohkohchi N

Abstract
BACKGROUND: Pancreatic acinar cell carcinoma (PACC), a rare variant of pancreatic malignancy, is generally managed the same way as pancreatic ductal adenocarcinoma (PDAC). Surgical resection is the gateway to curing it; however, once it metastasizes (usually to the liver, lungs, lymph nodes, or peritoneal cavity), systemic chemotherapy has been the only option, but with unfavorable results.
CASE PRESENTATION: A 67-year-old man with symptoms of loss of appetite and weight underwent surgery for malignancy of the pancreatic tail extending into the entire pancreas. The pathological diagnosis was PACC following total pancreatectomy. Twenty-four months after the pancreatectomy, a solitary liver metastasis was treated by partial hepatectomy, and, subsequently, 4 months later, he presented with melena. Further examination revealed a type-2 rectal tumor. Histological examination following biopsy revealed it to be rectal metastasis of PACC, and it was treated by abdominoperineal resection. Subsequently, the patient did not have tumor recurrence as of 40 months after pancreatectomy.
CONCLUSIONS: This is a rare case of PACC presenting with metachronal metastases in the liver and rectum, and we successfully treated them by surgical resections. Since the malignant behavior of PACC is usually less than that of PDAC, surgical resection could be an option even for metastatic lesions when the number and extent of metastases are limited.

PMID: 30075727 [PubMed - in process]

StatPearls

Fetched: July 20th, 2018, 5:00am GMT

StatPearls

Book. 2018 01

Authors:

Abstract
Bronchioloalveolar carcinoma (BAC) is a variant of non-small cell lung cancer (NSCLC) that in recent years has received a new identity and nomenclature from the histology perspective. The orphan among lung cancers has found a family, albeit with some newfound stepbrothers and sisters. The overhaul in the classification system of solitary adenocarcinomas has been driven by the purpose of identifying tumors that have an indolent clinical course and can be treated with the more conservative approach and a higher success rate. Until the previous decade, strict pathologic criteria defined a bronchioloalveolar carcinoma as a tumor arising from terminal bronchiolar and alveolar acinar epithelia with an absence of invasion through the alveolar basement membrane into the pulmonary parenchyma. A growing consensus has been to subclassify adenocarcinoma with radiologic features of ground glass opacities, with no or minimal extrathoracic spread, and histology demonstrating a lepidic growth pattern, in presence or absence of associated minimally invasive or invasive disease. The subgroup has been renamed adenocarcinoma with lepidic growth and classified into subtypes based on the extent of invasive disease.

PMID: 30020653

Permalink for 'Gastric neuroendocrine carcinoma with positive staining for prostate cancer markers including prostate-specific antigen and alpha-methylacyl-CoA racemase.'

Gastric neuroendocrine carcinoma with positive staining for prostate cancer markers including prostate-specific antigen and alpha-methylacyl-CoA racemase.

Fetched: July 18th, 2018, 5:00am GMT

Gastric neuroendocrine carcinoma with positive staining for prostate cancer markers including prostate-specific antigen and alpha-methylacyl-CoA racemase.

Urol Case Rep. 2018 Sep;20:67-69

Authors: Hakozaki Y, Murata T, Yokoyama M, Matsushima H, Ogawa M, Masuda T, Hirai Y, Kume H

Abstract
We report a case with prostate cancer and gastric neuroendocrine carcinoma. A 72-year old male presented with a gastric lesion 5 months after radical prostatectomy. The lesion was immunohistochemically positive for PSA, alpha-methylacyl-CoA racemase, synaptophysin, and chromogranin A, but negative for androgen receptor (AR). Differentiating gastric neuroendocrine carcinoma from gastric metastasis of prostate cancer is difficult, as both lesions exhibit similar acinar cell proliferation with prominent nucleoli.1 We discuss the diagnostic process of this case and how AR was a useful specific marker for diagnosing primary gastric neuroendocrine carcinoma.

PMID: 30009133 [PubMed]

Overexpression of SOX11 and TFE3 in Solid-Pseudopapillary Neoplasms of the Pancreas.

Fetched: July 18th, 2018, 5:00am GMT

Overexpression of SOX11 and TFE3 in Solid-Pseudopapillary Neoplasms of the Pancreas.

Am J Clin Pathol. 2017 Dec 20;149(1):67-75

Authors: Harrison G, Hemmerich A, Guy C, Perkinson K, Fleming D, McCall S, Cardona D, Zhang X

Abstract
Objectives: To characterize the expression of SOX11 and TFE3 proteins in solid-pseudopapillary neoplasms (SPNs) and their histologic mimickers.
Methods: Immunohistochemistry for SOX11, TFE3, and β-catenin was performed on 31 cases of surgically resected SPNs. Neuroendocrine tumors, acinar cell carcinomas, and pancreatoblastomas served as controls.
Results: Nuclear immunoreactivity for SOX11 was detected in all SPNs and five of 31 control tumors. Nuclear immunoreactivity for TFE3 was detected in 30 SPNs and three control tumors. Nuclear immunoreactivity for β-catenin was detected in all SPNs and four control tumors. The combination of three markers as immunohistochemical panels resulted in optimal sensitivity and specificity.
Conclusions: Both SOX11 and TFE3 were overexpressed in SPNs and may be involved in the pathogenesis. Clinically, SOX11 and TFE3 can be potentially used as diagnostic markers in distinguishing indeterminate SPNs from their histologic mimickers.

PMID: 29272888 [PubMed - indexed for MEDLINE]

Permalink for 'Primary Hepatoid Carcinoma of the Pancreas: A Clinicopathological Study of 3 Cases With Review of Additional 31 Cases in the Literature.'

Primary Hepatoid Carcinoma of the Pancreas: A Clinicopathological Study of 3 Cases With Review of Additional 31 Cases in the Literature.

Fetched: July 4th, 2018, 5:00am GMT

Primary Hepatoid Carcinoma of the Pancreas: A Clinicopathological Study of 3 Cases With Review of Additional 31 Cases in the Literature.

Int J Surg Pathol. 2018 Jun 01;:1066896918783468

Authors: Yang C, Sun L, Lai JZ, Zhou L, Liu Z, Xi Y, Tao Y, Dooley E, Cao D

Abstract
Primary pancreatic hepatoid carcinoma (PHC) is very rare. Here, we reported 3 such cases with review of additional 31 cases in the literature. Our 3 patients were male (83, 72, and 54 years old, respectively). Serum α-fetoprotein (AFP) was elevated in 1 patient (case 3, 8338 ng/mL) and not measured in the other two. The PHC in patient 1 (pathological stage pT2N0M0) and patient 2 (pT3N0M0) showed pure hepatocellular carcinoma (HCC)-like morphology, whereas in case 3 it was a PHC with true glandular differentiation (pT4N0M0). The diagnosis of PHC was confirmed with positive immunohistochemical staining in the tumor cells for AFP (2/3), Hep Par 1 (3/3), glypican-3 (2/3), arginase-1 (2/3), and Sal-like protein 4 (1/3). CD10 and polyclonal carcinoembryonic antigen stains show focal canalicular pattern in 2/3 tumors. Patient 1 did not receive further treatment after resection and was alive with no evidence of disease at 107 months. Patient 2 died of postoperative complications, whereas patient 3 received postsurgical chemoradiation and died of disease at 29 months. Our findings and literature review indicate that PHCs can be divided into 4 histological subtypes: with pure HCC-like morphology (n = 22), with neuroendocrine differentiation (n = 8), with true glandular differentiation (n = 3), and with acinar cell differentiation (n = 1). On univariate analysis, pure HCC-like morphology was associated with better disease-specific survival (DSS; P = .04), whereas lymph node and distant metastases were associated with worse DSS ( P = .002 for both). Age, gender, presenting symptoms, serum AFP level, and T stage were not associated with DSS. On multivariate analysis, none of these parameters was significantly associated with DSS.

PMID: 29961402 [PubMed - as supplied by publisher]

Prostatic Adenocarcinoma With Focal Pleomorphic Giant Cell Features: A Series of 30 Cases.

Fetched: June 28th, 2018, 5:00am GMT

Prostatic Adenocarcinoma With Focal Pleomorphic Giant Cell Features: A Series of 30 Cases.

Am J Surg Pathol. 2018 Jun 25;:

Authors: Alharbi AM, De Marzo AM, Hicks JL, Lotan TL, Epstein JI

Abstract
Prostatic adenocarcinoma with focal pleomorphic giant cell features is rare with the only prior series consisting of 6 cases. From 2005 to 2018, we identified 29 cases from our consult service and 1 case from our own institution. Men ranged in age from 39 to 90 years (median=75.5). Diagnostic specimens consisted of needle biopsies (n=13); transurethral resections (n=7), urethral/bladder biopsies (n=8), radical prostatectomy (n=1), and orchiectomy (n=1). In all cases, there was usual acinar prostatic adenocarcinoma, where the highest grade in all cases was Gleason score 9 to 10 (Grade Group 5). On average, 68% of the involved cores had cancer with a maximum percent of cancer averaging 55%; on average, transurethral resections had 85% of the area involved by cancer. Areas of cancer showing pleomorphic giant cell features were focal (<5%). Two of the needle biopsies showed extraprostatic extension. The radical prostatectomy had seminal vesicle invasion and positive margins with lymphovascular invasion. Prostatic adenocarcinoma with focal pleomorphic giant cell features is always accompanied by extensive usual acinar prostate adenocarcinoma where the highest grade in all cases was Gleason score 9 to 10 (Grade Group 5). Although the pleomorphic component is focal, it can mimic urothelial carcinoma. IHC can be misleading as PSA staining is often negative or focal in both the pleomorphic and usual prostatic adenocarcinoma components. NKX3.1 is the most sensitive prostate marker, but was still focal in 1 usual prostatic adenocarcinoma and negative in 2 pleomorphic components. Prostatic adenocarcinoma with focal pleomorphic giant cell features has a dismal prognosis. In men with no prior diagnosis of prostate adenocarcinoma and >1-year follow-up, 7/19 (37%) were dead at a median of 8 months after diagnosis. Of the 7 men with a prior history of prostate adenocarcinoma, 4/7 (57%) were dead at a median of 7 months after diagnosis of recurrent prostate adenocarcinoma with pleomorphic giant cell features.

PMID: 29944471 [PubMed - as supplied by publisher]

Permalink for 'Preoperative Treatment With FOLFIRINOX and Successful Resection for a Patient With Mixed Acinar-Endocrine Carcinoma of the Pancreas.'

Preoperative Treatment With FOLFIRINOX and Successful Resection for a Patient With Mixed Acinar-Endocrine Carcinoma of the Pancreas.

Fetched: June 27th, 2018, 5:00am GMT

Preoperative Treatment With FOLFIRINOX and Successful Resection for a Patient With Mixed Acinar-Endocrine Carcinoma of the Pancreas.

Pancreas. 2017 Apr;46(4):e32-e34

Authors: Sugimoto M, Hines OJ, Dawson DW, Muthusamy VR, Reber HA, Donahue TR

PMID: 28291165 [PubMed - indexed for MEDLINE]

Duct- and Acinar-Derived Pancreatic Ductal Adenocarcinomas Show Distinct Tumor Progression and Marker Expression.

Fetched: June 15th, 2018, 5:00am GMT

Duct- and Acinar-Derived Pancreatic Ductal Adenocarcinomas Show Distinct Tumor Progression and Marker Expression.

Cell Rep. 2017 Oct 24;21(4):966-978

Authors: Ferreira RMM, Sancho R, Messal HA, Nye E, Spencer-Dene B, Stone RK, Stamp G, Rosewell I, Quaglia A, Behrens A

Abstract
The cell of origin of pancreatic ductal adenocarcinoma (PDAC) has been controversial. Here, we show that identical oncogenic drivers trigger PDAC originating from both ductal and acinar cells with similar histology but with distinct pathophysiology and marker expression dependent on cell of origin. Whereas acinar-derived tumors exhibited low AGR2 expression and were preceded by pancreatic intraepithelial neoplasias (PanINs), duct-derived tumors displayed high AGR2 and developed independently of a PanIN stage via non-mucinous lesions. Using orthotopic transplantation and chimera experiments, we demonstrate that PanIN-like lesions can be induced by PDAC as bystanders in adjacent healthy tissues, explaining the co-existence of mucinous and non-mucinous lesions and highlighting the need to distinguish between true precursor PanINs and PanIN-like bystander lesions. Our results suggest AGR2 as a tool to stratify PDAC according to cell of origin, highlight that not all PanIN-like lesions are precursors of PDAC, and add an alternative progression route to the current model of PDAC development.

PMID: 29069604 [PubMed - indexed for MEDLINE]

Fibroblast-derived HGF drives acinar lung cancer cell polarization through integrin-dependent RhoA-ROCK1 inhibition.

Fetched: June 15th, 2018, 5:00am GMT

Fibroblast-derived HGF drives acinar lung cancer cell polarization through integrin-dependent RhoA-ROCK1 inhibition.

Cell Signal. 2017 Dec;40:91-98

Authors: Datta A, Sandilands E, Mostov KE, Bryant DM

Abstract
The formation of lumens in epithelial tissues requires apical-basal polarization of cells, and the co-ordination of this individual polarity collectively around a contiguous lumen. Signals from the Extracellular Matrix (ECM) instruct epithelia as to the orientation of where basal, and thus consequently apical, surfaces should be formed. We report that this pathway is normally absent in Calu-3 human lung adenocarcinoma cells in 3-Dimensional culture, but that paracrine signals from MRC5 lung fibroblasts can induce correct orientation of polarity and acinar morphogenesis. We identify HGF, acting through the c-Met receptor, as the key polarity-inducing morphogen, which acts to activate β1-integrin-dependent adhesion. HGF and ECM-derived integrin signals co-operate via a c-Src-dependent inhibition of the RhoA-ROCK1 signalling pathway via p190A RhoGAP. This occurred via controlling localization of these signalling pathways to the ECM-abutting surface of cells in 3-Dimensional culture. Thus, stromal derived signals can influence morphogenesis in epithelial cells by controlling activation and localization of cell polarity pathways.

PMID: 28888686 [PubMed - indexed for MEDLINE]

Aging dependent effect of nuclear tau.

Fetched: June 13th, 2018, 5:00am GMT

Aging dependent effect of nuclear tau.

Brain Res. 2017 Dec 15;1677:129-137

Authors: Gil L, Federico C, Pinedo F, Bruno F, Rebolledo AB, Montoya JJ, Olazabal IM, Ferrer I, Saccone S

Abstract
Tau protein is characterized by a complex pattern of phosphorylation and is localized in the cytoplasm and nucleus in both neuronal and non-neuronal cells. Human AT100 nuclear tau, endowed by phosphorylation in Thr212/Ser214, was recently shown to decline in cornus ammonis 1 (CA1) and dentate gyrus (DG) in Alzheimer's disease (AD), but a defined function for this nuclear tau remains unclear. Here we show that AT100 progressively increases in the nuclei of neuronal and non-neuronal cells during aging, and decreases in the more severe AD stages, as recently shown, and in cancer cells (colorectal adenocarcinoma and breast cancer). AT100, in addition to a co-localization with the DAPI-positive heterochromatin, was detected in the nucleolus of pyramidal cells from the CA1 region, shown to be at its highest level in the more senescent cells and in the first stage of AD (ADI), and disappearing in the more severe AD cases (ADIV). Taking into account the nuclear distribution of AT100 during cell aging and its relation to the chromatin changes observed in degenerated neurons, as well as in cancerous cells, which are both cellular pathologies associated with age, we can consider the Thr212/Ser214 phosphorylated nuclear tau as a molecular marker of cell aging.

PMID: 28974363 [PubMed - indexed for MEDLINE]

Bioengineered Submucosal Organoids for In Vitro Modeling of Colorectal Cancer.

Fetched: June 13th, 2018, 5:00am GMT

Bioengineered Submucosal Organoids for In Vitro Modeling of Colorectal Cancer.

Tissue Eng Part A. 2017 Oct;23(19-20):1026-1041

Authors: Devarasetty M, Skardal A, Cowdrick K, Marini F, Soker S

Abstract
The physical nature of the tumor microenvironment significantly impacts tumor growth, invasion, and response to drugs. Most in vitro tumor models are designed to study the effects of extracellular matrix (ECM) stiffness on tumor cells, while not addressing the effects of ECM's specific topography. In this study, we bioengineered submucosal organoids, using primary smooth muscle cells embedded in collagen I hydrogel, which produce aligned and parallel fiber topography similar to those found in vivo. The fiber organization in the submucosal organoids induced an epithelial phenotype in spheroids of colorectal carcinoma cells (HCT-116), which were embedded within the organoids. Conversely, unorganized fibers drove a mesenchymal phenotype in the tumor cells. HCT-116 cells in organoids with aligned fibers showed no WNT signaling activation, and conversely, WNT signaling activation was observed in organoids with disrupted fibers. Consequently, HCT-116 cells in the aligned condition exhibited decreased cellular proliferation and reduced sensitivity to 5-fluorouracil chemotherapeutic treatment compared to cells in the unorganized construct. Collectively, the results establish a unique colorectal tumor organoid model to study the effects of stromal topography on cancer cell phenotype, proliferation, and ultimately, chemotherapeutic susceptibility. In the future, such organoids can utilize patient-derived cells for precision medicine applications.

PMID: 28922975 [PubMed - indexed for MEDLINE]

Permalink for 'Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases.'

Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases.

Fetched: June 13th, 2018, 5:00am GMT

Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases.

Histopathology. 2017 Oct;71(4):641-647

Authors: Samaratunga H, Delahunt B, Srigley JR, Yaxley J, Johannsen S, Coughlin G, Gianduzzo T, Kua B, Patterson I, Nacey JN, Egevad L

Abstract
AIM: The clinical significance of mucinous prostatic adenocarcinoma (PCa) remains uncertain.
METHODS: From 6440 cases of PCa treated by radical prostatectomy from 2009 to 2014, mucinous components of 5-100% were found in 143 (2.2%) cases.
RESULTS: The mean age was 61.4 years, mean pre-operative serum prostate-specific antigen (PSA) was 7.8 ng/ml and clinical stage category was cT1 in 81% and cT2 in 19% of cases. Cases were graded using the 2014 International Society of Urological Pathology recommendation of grading underlying architecture, and Gleason scores (GS) were 3 + 4 in 13.3%, 4 + 3 in 54.5%, 4 + 4 in 2.1%, 3 + 4 or 4 + 3 with tertiary 5 in 11.9% and 9-10 in 18.2%. The mucinous component invariably had a high-grade component. Extraprostatic extension was found in 46.8% of cases. In 21.6%, tumour volume was ≥3 cm³ and 9.7% had surgical margin positivity. Seminal vesicle involvement was found in 6.9%. In 73 cases the mucinous component was >25%, and when cases were divided on the basis of the area of mucin present (≤25 versus >25%) there was no significant difference between clinical or pathological features. Similar findings were achieved when cases were compared with grade-matched non-mucinous carcinoma controls. The 5-year biochemical recurrence rates for mucinous versus non-mucinous cancer were 12.5 versus 17% (P = 0.15).
CONCLUSION: PCa with mucinous components is often high grade; however, the prognosis appears to be similar to non-mucinous cancers of similar GS.

PMID: 28590015 [PubMed - indexed for MEDLINE]

Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate.

Fetched: June 11th, 2018, 5:00am GMT

Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate.

Hum Pathol. 2018 Jun 06;:

Authors: Xue W, Xin Z, Zhang Y, Jiang Z, Zhao L, Fan L, Wang Y, Xie S, Shangguan X, Zhu Y, Pan J, Liu Q, Huang Y, Dong B

Abstract
The correct diagnosis of small cell carcinoma (SCC) of the prostate is critical because of its aggressive behavior and poor prognosis. The histopathologic diagnosis could be challenging without neuroendocrine markers, which currently has limitations. Insulinomaassociated protein 1 (INSM1), a zinc-finger transcription factor, is considered to play an important role in the development of several neuroendocrine precursor cells. Its diagnosis value has only recently been evaluated. In this study, we analyzed the expression of INSM in three high-throughput RNA sequencing data sets and performed INSM1 immunohistochemistry on a large series of prostatic SCCs and nonneuroendocrine prostate tissues. To validate its possible utility as a diagnostic marker, the performance of chromogranin and synaptophysin was used for comparison. We found INSM1 mRNA is upregulated in neuroendocrine prostate carcinoma samples from the published data sets. The results were verified by the immunohistochemistry performance. INSM1 was positive in 92.3% of prostatic SCCs, compared with 53.8% positive for chromogranin, and 84.6% positive for synaptophysin. INSM1 was also stained all of the mixed SCC-acinar adenocarcinomas and metastatic SCCs progression from acinar adenocarcinoma. Only 3.4% of benign prostate tissues and 4.0% of prostate adenocarcinomas were INSM1 positive. Our data suggest that INSM1 is a novel sensitive and specific marker for detection of SCC of the prostate. Application of INSM1 in clinical pathologic diagnosis will be valuable.

PMID: 29885405 [PubMed - as supplied by publisher]

Hepatoid Adenocarcinoma of Unknown Primary Masquerading as a Pancreatic Tumor.

Fetched: June 8th, 2018, 5:00am GMT

Hepatoid Adenocarcinoma of Unknown Primary Masquerading as a Pancreatic Tumor.

J Gastrointest Surg. 2017 Dec;21(12):2132-2134

Authors: Dogeas E, Peng L, Choti MA

Abstract
Hepatoid adenocarcinoma is a rare type of extrahepatic cancer characterized by hepatocellular carcinoma-like histology. We present a case of a large solitary mass in the peripancreatic region found to be an isolated lymph node metastasis from an unknown primary hepatoid adenocarcinoma masquerading as an acinar carcinoma of the pancreas.

PMID: 28681213 [PubMed - indexed for MEDLINE]

Permalink for 'Clinical characteristics and prognosis of patients with lung adenosquamous carcinoma after surgical resection: results from two institutes.'

Clinical characteristics and prognosis of patients with lung adenosquamous carcinoma after surgical resection: results from two institutes.

Fetched: June 2nd, 2018, 5:00am GMT

Clinical characteristics and prognosis of patients with lung adenosquamous carcinoma after surgical resection: results from two institutes.

J Thorac Dis. 2018 Apr;10(4):2397-2402

Authors: Zhu L, Jiang L, Yang J, Gu W, He J

Abstract
Background: Adenosquamous carcinoma (ASC) is a mixed glandular and squamous cell carcinoma (SCC) with more aggressive behavior than the other histologic subtypes of lung cancer. We aim to evaluate the prognosis of patients with ASC after surgical resection.
Methods: We reviewed records of patients who underwent surgical resection for lung cancer in two institutes between January 2010 and December 2015. Survival data were collected with a median follow-up of 59 (range from 10 to 85) months. Kaplan-Meier survival curve was determined for all patients.
Results: Patients with ASC accounted for 1.6% of all NSCLC patients (33 males, 25 females). The cumulative postoperative 3- and 5-year survival rates were 56% and 48%, respectively. Overall survival (OS) was significantly lower in ASC patients than in adenocarcinoma (AC) patients operated during the same period (P<0.01). Patients with ASC containing acinar predominant AC had better survival than those with non-acinar predominant ASC (P=0.03). No difference of OS was found in patients with or without visceral pleural invasion (VPI), vascular invasion (VI) or EGFR mutation status. Multivariate analysis showed gender, pathological subtype, and TNM staging to be independent prognostic factors.
Conclusions: We demonstrated that ASC were uncommon and aggressive lung tumors. Predominant histological subtype of AC might be an independent prognostic factor for ASC. Further prospective studies are warranted to clarify the characteristics of this rare tumor.

PMID: 29850145 [PubMed]

Accuracy of preoperative fine needle aspiration in diagnosis of malignant parotid tumors.

Fetched: June 1st, 2018, 5:00am GMT

Accuracy of preoperative fine needle aspiration in diagnosis of malignant parotid tumors.

Saudi Med J. 2017 Oct;38(10):1000-1006

Authors: Marzouki HZ, Altabsh MA, Albakrei MO, Al-Khatib TA, Merdad MA, Farsi NJ

Abstract
OBJECTIVES: To determine the diagnostic accuracy of fine needle aspiration (FNA) for detecting malignant parotid tumors. Methods: We conducted a retrospective study of all patients diagnosed with benign or malignant parotid gland tumors in King Abdulaziz University Hospital, Jeddah, Saudi Arabia, between January 2004 and May 2015. The records of 65 subjects were obtained. Histopathological findings and data from FNA examinations were obtained from medical records. Twenty-three subjects were excluded due to missing FNA, histopathology results or both. The sensitivity, specificity, negative predictive value, and positive predictive value of FNA for detecting malignant lesions were estimated and compared with the gold standard, histopathology. Results: The specimens of 5 cases were insufficient for diagnosis; therefore, 38 cases were diagnosed by FNA and had histopathological reports. Three cases were diagnosed positive for cancer using histopathology and missed by FNA, 3 were diagnosed as malignant lesions using both FNA and histopathology, and 32 cases were determined benign based on histopathology and FNA analysis. The total prevalence of parotid malignancies was 15.8%. The sensitivity of FNA for detecting malignancy was 50%, and the specificity was 100%; with a positive predictive value of 100% and negative predictive value of 91.4%. Conclusion: Fine needle aspiration is a highly specific, but only moderately sensitive test. We support the use of this method as an initial tool for diagnosing parotid gland malignancies, as it is a safe, rapid, and painless procedure, compared to histopathology.

PMID: 28917063 [PubMed - indexed for MEDLINE]

XAV939 inhibits the proliferation and migration of lung adenocarcinoma A549 cells through the WNT pathway.

Fetched: May 31st, 2018, 5:00am GMT

XAV939 inhibits the proliferation and migration of lung adenocarcinoma A549 cells through the WNT pathway.

Oncol Lett. 2018 Jun;15(6):8973-8982

Authors: Li C, Zheng X, Han Y, Lv Y, Lan F, Zhao J

Abstract
The present study assessed the effects of the tankyrase (TNKS) small molecule inhibitor XAV939 on the proliferation and migration of lung adenocarcinoma A549 cells and the possible underlying mechanism. To do this, the association between TNKS and the WNT/β-catenin signaling pathway in lung acinar adenocarcinoma was investigated. Immunohistochemistry was performed, which demonstrated that TNKS, β-catenin and Myc proto-oncogene protein (c-Myc) proteins are positively expressed in lung adenocarcinoma tissue; this expression was significantly higher than that in normal adjacent non-carcinoma tissues. A549 cell proliferation was inhibited in all XAV939-intervention groups examined. In the wound-healing assay, cells treated with different concentrations of XAV939 exhibited a significantly increased scratch width compared with the control group. Reverse transcription-semi-quantitative polymerase chain reaction analysis revealed that β-catenin mRNA expression was significantly decreased in A549 cells in response to different XAV939 concentrations compared with the control group. Immunofluorescence revealed that β-catenin protein, initially localized in the nucleus/cytoplasm, gradually translocated to the cytoplasm/membrane, an effect that was associated with increased drug concentration. TNKS, β-catenin and c-Myc protein expression in A549 cells treated with XAV939 was reduced compared with that in untreated cells. Therefore, abnormally high TNKS expression may promote the occurrence of lung cancer. The TNKS inhibitor XAV939 inhibited lung adenocarcinoma A549 cell proliferation and migration in vitro. The underlying mechanism by which XAV939 exerted its inhibitory effects may be associated with attenuation of the WNT signaling pathway.

PMID: 29805633 [PubMed]

Permalink for 'Pulmonary adenocarcinoma with high-grade fetal adenocarcinoma component has a poor prognosis, comparable to that of micropapillary adenocarcinoma.'

Pulmonary adenocarcinoma with high-grade fetal adenocarcinoma component has a poor prognosis, comparable to that of micropapillary adenocarcinoma.

Fetched: May 25th, 2018, 5:00am GMT

Pulmonary adenocarcinoma with high-grade fetal adenocarcinoma component has a poor prognosis, comparable to that of micropapillary adenocarcinoma.

Mod Pathol. 2018 May 21;:

Authors: Suzuki M, Nakatani Y, Ito H, Narimatsu H, Yamada K, Yoshioka E, Washimi K, Okubo Y, Kawachi K, Miyagi Y, Yokose T

Abstract
Fetal adenocarcinoma is a rare variant of lung adenocarcinoma, which is subcategorized into low-grade and high-grade forms. High-grade fetal adenocarcinoma confers worse prognosis than low-grade fetal adenocarcinoma, but the prognostic differences between high-grade fetal adenocarcinoma and conventional lung adenocarcinoma are unknown. We reviewed tissue sections of 3719 cases of surgically resected primary lung cancers and found 53 lung cancers with a high-grade fetal adenocarcinoma component. We analyzed their clinicopathological and immunohistochemical features, and performed a prognostic analysis of adenocarcinomas with the fetal-type component. We further analyzed the prognostic differences between adenocarcinomas with the fetal-type component and conventional adenocarcinomas without the fetal-type component. Lung cancers with the fetal-type component predominantly occurred in elderly men with a smoking history. Twenty-nine patients had stage I disease, 13 patients had stage II, and 11 patients had stage III. The fetal-type histology was combined with conventional-type adenocarcinoma (41 cases), squamous cell carcinoma (5 cases), large cell neuroendocrine carcinoma (5 cases), enteric adenocarcinoma (2 cases), and small cell carcinoma (1 case). The fetal-type component showed immunopositivity for α-fetoprotein (39%), glypican-3 (37%), and SALL4 (17%). The 5-year overall survivals of fetal-type-predominant and fetal-type-nonpredominant patients were 44 and 56%, respectively (P = 0.962). The 5-year overall survivals of lepidic-, acinar-, papillary-, solid-, and micropapillary-predominant adenocarcinomas, invasive mucinous adenocarcinomas, and adenocarcinomas with the fetal-type component were 94, 82, 77, 69, 57, 83, and 41%, respectively (P < 0.001). Univariate and multivariate analyses showed that adenocarcinomas with the fetal-type component had a significantly lower overall survival rate than the other histological subtypes, except for the micropapillary-predominant subtype. Our study demonstrated that adenocarcinomas with the fetal-type component had a poor prognosis that was comparable to that of micropapillary adenocarcinoma. The presence of the high-grade fetal adenocarcinoma component in lung adenocarcinomas is an important prognostic marker.

PMID: 29785018 [PubMed - as supplied by publisher]

[Acquired cystic kidney disease-associated renal cell carcinoma: a clinicopathologic study of three cases].

Fetched: May 25th, 2018, 5:00am GMT

[Acquired cystic kidney disease-associated renal cell carcinoma: a clinicopathologic study of three cases].

Zhonghua Bing Li Xue Za Zhi. 2018 May 08;47(5):366-371

Authors: Zhang W, Xu LL, Yu WJ, Wang Q, Jiang YX, Liu Y, Li YJ

Abstract
Objective: To study the clinicopathologic, immunohistochemical (IHC), histogenetic and prognostic features of acquired cystic kidney disease-associated renal cell carcinoma (ACKD-RCC). Methods: Three cases of ACKD-RCC, including two from 401 Hospital of PLA and one from the Affiliated Hospital of Qingdao University were studied by clinical, histological and IHC analysis with review of relevant literature. Results: All the three patients were male, ranging from 46 to 78 years old. All patients had history of chronic renal failure; two patients were treated with hemodialysis for 9 years and 11 years, respectively. In two cases the tumor sizes were 2.5 cm and 3.5 cm, respectively, and the tumor border was distinct. The remaining case showed extensive renal hemorrhage with an inconspicuous mass. Microscopically, the tumor cells were arranged in cribriform, microcystic or acinar structures, with variable papillary structure in one case. Hemorrhage of varying degrees was seen in all three cases, and obvious necrosis was noted in two. The tumor cells had deeply eosinophilic cytoplasm, indistinct cell border, round or oval nuclei, and prominent nucleoli (WHO/ISUP grade 3). Mitoses were rare. Abundant oxalate crystals were seen in two cases. The renal mesenchyme of all three cases were atrophic with variable cystic changes of the renal tubules, the lining cells showed atypical hyperplasia. IHC staining showed all tumors were diffusely positive for vimentin, CD10, RCC, CAM5.2, P504s and mitochondria in the cytoplasm, and were variably positive for EMA (2/3), CK7 (1/3), CA9 (1/3) and PAX8 (3/3). All cases were negative for CD117, HMB45, Melan A and TFE3. After 3-14 months follow-up, one patient died from renal failure six months after surgery. The other two patients were alive without tumor recurrence or metastasis. Conclusions: ACKD-RCC is a very rare renal cell carcinoma. The specific cribriform structure, deeply eosinophilic cytoplasm, prominent nucleoli (WHO/ISUP grade 3), and oxalate crystals deposition, associated with the history of ACKD could aid the diagnosis. ACKD-RCC arises from the proximal renal tubule and its histogenesis might be associated with proliferation and malignant change of the atypical epithelial cells of the cystic renal tubules. ACKD-RCC may have a favorable prognosis except for tumors with sarcomatoid differentiation.

PMID: 29783804 [PubMed - in process]

Permalink for 'Phospho-valproic acid inhibits pancreatic cancer growth in mice: enhanced efficacy by its formulation in poly-(L)-lactic acid-poly(ethylene glycol) nanoparticles.'

Phospho-valproic acid inhibits pancreatic cancer growth in mice: enhanced efficacy by its formulation in poly-(L)-lactic acid-poly(ethylene glycol) nanoparticles.

Fetched: May 25th, 2018, 5:00am GMT

Phospho-valproic acid inhibits pancreatic cancer growth in mice: enhanced efficacy by its formulation in poly-(L)-lactic acid-poly(ethylene glycol) nanoparticles.

Int J Oncol. 2017 Oct;51(4):1035-1044

Authors: Mattheolabakis G, Wang R, Rigas B, Mackenzie GG

Abstract
Pancreatic cancer (PC) is one of the most difficult cancers to treat. Since the current chemotherapy is inadequate and various biological approaches have failed, the need for agents that have a potential to treat PC is pressing. Phospho-valproic acid (P-V), a novel anticancer agent, is efficacious in xenograft models of human PC and is apparently safe. In the present study, we evaluated whether formulating P-V in nanoparticles could enhance its anticancer efficacy. In a mouse model of Kras/pancreatitis-associated PC, P-V, orally administered, inhibited the incidence of acinar-to-ductal metaplasia by 60%. To improve its efficacy, we formulated P-V in five different polymeric nanoparticles. Poly-(L)-lactic acid- poly(ethylene glycol) (PLLA-PEG) nanoparticles proved the optimal formulation. PLLA-PEG improved P-V's pharmacokinetics in mice enhancing the levels of P-V in blood. Compared to control, P-V formulated in PLLA-PEG suppressed the growth of MIA PaCa-2 xenografts by 81%, whereas P-V alone reduced it by 51% (p<0.01). Furthermore, P-V formulated in PLLA-PEG inhibited acinar-to-ductal metaplasia in mice with activated Kras, reducing it by 87% (p<0.02). In both disease models, P-V suppressed STAT3 phosphorylation at the Ser727 and Tyr705 residues; STAT3 is the pivotal molecular target of P-V. In conclusion, P-V is a promising agent against PC, and its formulation in PLLA-PEG nanoparticles enhances its efficacy by improving its pharmacokinetics.

PMID: 28849098 [PubMed - indexed for MEDLINE]

Molecular Diagnostics in the Neoplasms of the Pancreas, Liver, Gallbladder, and Extrahepatic Biliary Tract: 2018 Update.

Fetched: May 21st, 2018, 5:00am GMT

Molecular Diagnostics in the Neoplasms of the Pancreas, Liver, Gallbladder, and Extrahepatic Biliary Tract: 2018 Update.

Clin Lab Med. 2018 Jun;38(2):367-384

Authors: Zhang L, Bluth MH, Bhalla A

Abstract
Pancreatic neoplasms, including ductal adenocarcinoma, solid pseudopapillary neoplasm, pancreatic endocrine neoplasms, acinar cell carcinoma, and pancreatoblastoma, are associated with different genetic abnormalities. Hepatic adenomas with beta-catenin exon 3 mutation are associated with a high risk of malignancy. Hepatic adenoma with arginosuccinate synthetase 1 expression or sonic hedgehog mutations are associated with a risk of bleeding. Hepatocellular carcinoma and choangiocarcinoma display heterogeneity at both morphologic and molecular levels Cholangiocellular carcinoma is most commonly associated with IDH 1/2 mutations.

PMID: 29776636 [PubMed - in process]

Permalink for 'GRP78 haploinsufficiency suppresses acinar-to-ductal metaplasia, signaling, and mutant Kras-driven pancreatic tumorigenesis in mice.'

GRP78 haploinsufficiency suppresses acinar-to-ductal metaplasia, signaling, and mutant Kras-driven pancreatic tumorigenesis in mice.

Fetched: May 17th, 2018, 5:00am GMT

GRP78 haploinsufficiency suppresses acinar-to-ductal metaplasia, signaling, and mutant Kras-driven pancreatic tumorigenesis in mice.

Proc Natl Acad Sci U S A. 2017 05 16;114(20):E4020-E4029

Authors: Shen J, Ha DP, Zhu G, Rangel DF, Kobielak A, Gill PS, Groshen S, Dubeau L, Lee AS

Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal disease in critical need of new therapeutic strategies. Here, we report that the stress-inducible 78-kDa glucose-regulated protein (GRP78/HSPA5), a key regulator of endoplasmic reticulum homeostasis and PI3K/AKT signaling, is overexpressed in the acini and PDAC of Pdx1-Cre;KrasG12D/+;p53f/+ (PKC) mice as early as 2 mo, suggesting that GRP78 could exert a protective effect on acinar cells under stress, as during PDAC development. The PKC pancreata bearing wild-type Grp78 showed detectable PDAC by 3 mo and rapid subsequent tumor growth. In contrast, the PKC pancreata bearing a Grp78f/+ allele (PKC78f/+ mice) expressing about 50% of GRP78 maintained normal sizes during the early months, with reduced proliferation and suppression of AKT, S6, ERK, and STAT3 activation. Acinar-to-ductal metaplasia (ADM) has been identified as a key tumor initiation mechanism of PDAC. Compared with PKC, the PKC78f/+ pancreata showed substantial reduction of ADM as well as pancreatic intraepithelial neoplasia-1 (PanIN-1), PanIN-2, and PanIN-3 and delayed onset of PDAC. ADM in response to transforming growth factor α was also suppressed in ex vivo cultures of acinar cell clusters isolated from mouse pancreas bearing targeted heterozygous knockout of Grp78 (c78f/+ ) and subjected to 3D culture in collagen. We further discovered that GRP78 haploinsufficiency in both the PKC78f/+ and c78f/+ pancreata leads to reduction of epidermal growth factor receptor, which is critical for ADM initiation. Collectively, our studies establish a role for GRP78 in ADM and PDAC development.

PMID: 28461470 [PubMed - indexed for MEDLINE]

The screening and electron microscopy observation of mammary analogue secretory carcinoma in Chinese.

Fetched: May 14th, 2018, 5:00am GMT

The screening and electron microscopy observation of mammary analogue secretory carcinoma in Chinese.

J Craniomaxillofac Surg. 2017 Oct 19;:

Authors: Zhong Y, Liu L, Qi B, Song X, Shen L, Li H

Abstract
Mammary analogue secretory carcinoma of salivary gland (MASC) is a tumor with histopathologic and immunophenotypic features mimicking secretory carcinoma of the breast harboring the ETV6 split. The expression of mammaglobin, S-100, Ki-67, P63 and ETV6 split were detected in twelve cases of acinar cell carcinoma and fourteen cases of mammary analogue secretory carcinoma of salivary gland by immunohistochemistry and fluorescence in situ hybridization respectively. The expression of ETV6 gene split was detected in fourteen mammary analogue secretory carcinomas of salivary gland with positive expression of mammaglobin. Eight of mammary analogue secretory carcinomas of salivary gland also tested positive for the ETV6 gene split via fluorescence in-situ hybridization (FISH). The concordance rate of the immunohistochemistry and FISH was 72.3%. Mammaglobin and ETV6 gene split detection could help to distinguish mammary analogue secretory carcinoma of salivary gland. The mammary analogue secretory carcinoma of salivary gland specimens were also examined under transmission electron microscope. And apical junctional complexes were observed in the loosely connected tumor cells.

PMID: 29752049 [PubMed - as supplied by publisher]

Central Acinic Cell Carcinoma of the Mandible Simulating as Benign Odontogenic Lesion: A Case Report.

Fetched: May 13th, 2018, 5:00am GMT

Central Acinic Cell Carcinoma of the Mandible Simulating as Benign Odontogenic Lesion: A Case Report.

Iran J Med Sci. 2018 Mar;43(2):223-226

Authors: Bajpai M, Pardhe N, Chandolia B, Arora M

Abstract
Centrally occurring salivary gland tumors are rare. Because of a considerable overlap between the clinical and histopathological features, this group of tumors often produces a diagnostic difficulty to the clinicians and oral pathologists. Acinic cell carcinoma (ACC) is an unusual, low-grade, malignant salivary gland tumor that represents approximately 2% of the salivary gland tumors with almost 90% arising in the parotid gland. The rest involve the submandibular and the minor salivary gland. ACC of the jaw is extremely rare and, to our knowledge, only 8 cases have been reported in the English literature. Herein, a case of primary intraosseous ACC of the mandible in a 31-year-old woman is presented. The present case is unique, as the central ACC has never been reported in a patient in the third decade of life. The complete surgical removal of the tumor was carried out under general anesthesia along with the extraction of teeth #31, #32, #41, and #42. The follow-up period of 1-year was uneventful.

PMID: 29749993 [PubMed]

Permalink for 'Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice.'

Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice.

Fetched: May 11th, 2018, 5:00am GMT

Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice.

Gastroenterology. 2018 04;154(5):1494-1508.e13

Authors: He P, Yang JW, Yang VW, Bialkowska AB

Abstract
BACKGROUND & AIMS: Activating mutations in KRAS are detected in most pancreatic ductal adenocarcinomas (PDACs). Expression of an activated form of KRAS (KrasG12D) in pancreata of mice is sufficient to induce formation of pancreatic intraepithelial neoplasia (PanINs)-a precursor of PDAC. Pancreatitis increases formation of PanINs in mice that express KrasG12D by promoting acinar-to-ductal metaplasia (ADM). We investigated the role of the transcription factor Krüppel-like factor 5 (KLF5) in ADM and KRAS-mediated formation of PanINs.
METHODS: We performed studies in adult mice with conditional disruption of Klf5 (Klf5fl/fl) and/or expression of KrasG12D (LSL-KrasG12D) via CreERTM recombinase regulated by an acinar cell-specific promoter (Ptf1a). Activation of KrasG12D and loss of KLF5 was achieved by administration of tamoxifen. Pancreatitis was induced in mice by administration of cerulein; pancreatic tissues were collected, analyzed by histology and immunohistochemistry, and transcriptomes were compared between mice that did or did not express KLF5. We performed immunohistochemical analyses of human tissue microarrays, comparing levels of KLF5 among 96 human samples of PDAC. UN-KC-6141 cells (pancreatic cancer cells derived from Pdx1-Cre;LSL-KrasG12D mice) were incubated with inhibitors of different kinases and analyzed in proliferation assays and by immunoblots. Expression of KLF5 was knocked down with small hairpin RNAs or CRISPR/Cas9 strategies; cells were analyzed in proliferation and gene expression assays, and compared with cells expressing control vectors. Cells were subcutaneously injected into flanks of syngeneic mice and tumor growth was assessed.
RESULTS: Of the 96 PDAC samples analyzed, 73% were positive for KLF5 (defined as nuclear staining in more than 5% of tumor cells). Pancreata from Ptf1a-CreERTM;LSL-KrasG12D mice contained ADM and PanIN lesions, which contained high levels of nuclear KLF5 within these structures. In contrast, Ptf1a-CreERTM;LSL-KrasG12D;Klf5fl/fl mice formed fewer PanINs. After cerulein administration, Ptf1a-CreERTM;LSL-KrasG12D mice formed more extensive ADM than Ptf1a-CreERTM;LSL-KrasG12D;Klf5fl/fl mice. Pancreata from Ptf1a-CreERTM;LSL-KrasG12D;Klf5fl/fl mice had increased expression of the tumor suppressor NDRG2 and reduced phosphorylation (activation) of STAT3, compared with Ptf1a-CreERTM;LSL-KrasG12D mice. In UN-KC-6141 cells, PI3K and MEK signaling increased expression of KLF5; a high level of KLF5 increased proliferation. Cells with knockdown of Klf5 had reduced proliferation, compared with control cells, had reduced expression of ductal markers, and formed smaller tumors (71.61 ± 30.79 mm3 vs 121.44 ± 34.90 mm3 from control cells) in flanks of mice.
CONCLUSION: Levels of KLF5 are increased in human PDAC samples and in PanINs of Ptf1a-CreERTM;LSL-KrasG12D mice, compared with controls. KLF5 disruption increases expression of NDRG2 and reduces activation of STAT3 and reduces ADM and PanINs formation in mice. Strategies to reduce KLF5 activity might reduce progression of acinar cells from ADM to PanIN and pancreatic tumorigenesis.

PMID: 29248441 [PubMed - indexed for MEDLINE]

Acelarin First Line Randomised Pancreatic Study

Posted: August 1st, 2018, 2:00pm GMT

Conditions: Pancreatic Acinar Carcinoma; Pancreatic Neoplasms
Interventions: Drug: Acelarin; Drug: Gemcitabine
Sponsors: The Clatterbridge Cancer Centre NHS Foundation Trust; Cancer Research UK; University of Liverpool
Recruiting

Incidence of POPF in the Resection of the Left Pancreas With RFAT

Posted: June 27th, 2018, 2:00pm GMT

Conditions: Pancreas Neoplasm; Pancreas Cancer; Pancreatic Adenocarcinoma; Benign Pancreas Tumor
Intervention:
Sponsor: Hospital del Mar
Recruiting

Acinic Cell Carcinoma - News-Medical.net

Posted: June 20th, 2018, 11:23pm GMT

News-Medical.net

【暖势力】展现韧力宣扬癌症非绝症．抗癌女斗士远征俄高峰 - 星洲网 Sin Chew Daily (新闻发布)

Posted: May 21st, 2018, 7:25am GMT

星洲网 Sin Chew Daily (新闻发布)

【暖势力】展现韧力宣扬癌症非绝症．抗癌女斗士远征俄高峰
星洲网 Sin Chew Daily (新闻发布)
但到了2014年，癌症再度找上她，此番前来的是腺泡细胞癌（Acinic Cell Carcinoma），而她选择通过割除右侧腮腺手术来保命，以继续她冒险的人生旅程。迈拉代表马来西亚登上厄尔布鲁斯峰，山上一望无际的风景和强风飞雪 ...

JAMA Otolaryngology–Head & Neck Surgery - JAMA: The Journal of the American Medical Association

Posted: October 6th, 2016, 5:10pm GMT

JAMA: The Journal of the American Medical Association

JAMA Otolaryngology–Head & Neck Surgery
JAMA: The Journal of the American Medical Association
Close Margins and Adjuvant Radiotherapy in Acinic Cell Carcinoma of the Parotid Gland. Joseph Zenga, MD; et al. Original Investigation. online first. Joseph Zenga, MD; et al. Opinion. The Role of Migraine in Hearing and Balance Symptoms. Harrison W ...

Mammary analog secretory carcinoma, low-grade salivary duct carcinoma, and mimickers: a comparative study - Nature.com

Posted: June 19th, 2015, 9:41am GMT

Nature.com

Mammary analog secretory carcinoma, low-grade salivary duct carcinoma, and mimickers: a comparative study
Nature.com
We describe 14 new MASCs and examine their immunophenotypic and genetic profiles in the context of look-alikes, namely, low-and high-grade salivary duct carcinoma and acinic cell carcinoma. ETV6 rearrangement, and robust expression of mammaglobin ...

Proton Therapy: A Better Way to Destroy Tumors - Memorial Sloan Kettering Cancer Center (blog)

Posted: February 17th, 2015, 12:29pm GMT

Memorial Sloan Kettering Cancer Center (blog)

Proton Therapy: A Better Way to Destroy Tumors
Memorial Sloan Kettering Cancer Center (blog)
While proton therapy kills cancer cells through a process similar to that used in x-ray radiation — by damaging their DNA — the unique physical properties of protons allow them to deliver the dose at a specific depth in the body. With proton therapy ...

[Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].

Fetched: August 17th, 2018, 5:00am GMT

[Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].

Zhonghua Bing Li Xue Za Zhi. 2018 Aug 08;47(8):574-579

Authors: Zhao YN, Wang XT, Xia QY, Wang GP, Sun SY, Zhao LF, Zhou XJ, Rao Q

PMID: 30107660 [PubMed - in process]

Pancreatic Acinar Cell Carcinoma with Multiple Liver Metastases Effectively Treated by S-1 Chemotherapy.

Fetched: August 15th, 2018, 5:00am GMT

Pancreatic Acinar Cell Carcinoma with Multiple Liver Metastases Effectively Treated by S-1 Chemotherapy.

Intern Med. 2018 Aug 10;:

Authors: Yoshida N, Kanno A, Masamune A, Nabeshima T, Hongo S, Miura S, Takikawa T, Hamada S, Kikuta K, Kume K, Ueno M, Shimosegawa T

PMID: 30101903 [PubMed - as supplied by publisher]

Pancreatic Mass in a Patient With an Increased Serum Level of IgG4.

Fetched: August 10th, 2018, 5:00am GMT

Pancreatic Mass in a Patient With an Increased Serum Level of IgG4.

Gastroenterology. 2018 08;155(2):269-270

Authors: Matsumori T, Shiokawa M, Kodama Y

PMID: 29410043 [PubMed - indexed for MEDLINE]

[Clinicopathologic and molecular genetic analysis of secretory carcinoma of salivary gland].

Fetched: August 8th, 2018, 5:00am GMT

[Clinicopathologic and molecular genetic analysis of secretory carcinoma of salivary gland].

Zhonghua Kou Qiang Yi Xue Za Zhi. 2018 Aug 09;53(8):533-538

Authors: Zhao M, Zhao DH, Cheng G, Yan YJ, Wang Z, He XL

PMID: 30078266 [PubMed - in process]

Surgical resection of hepatic and rectal metastases of pancreatic acinar cell carcinoma (PACC): a case report.

Fetched: August 6th, 2018, 5:00am GMT

Surgical resection of hepatic and rectal metastases of pancreatic acinar cell carcinoma (PACC): a case report.

World J Surg Oncol. 2018 Aug 03;16(1):158

Authors: Ohara Y, Oda T, Enomoto T, Hisakura K, Akashi Y, Ogawa K, Owada Y, Domoto Y, Miyazaki Y, Shimomura O, Kurata M, Ohkohchi N

PMID: 30075727 [PubMed - in process]

Sclerosing polycystic adenosis of the oral cavity.

Fetched: July 30th, 2018, 5:00am GMT

Sclerosing polycystic adenosis of the oral cavity.

Br J Oral Maxillofac Surg. 2018 Jul 24;:

Authors: Mumtaz S, Ali A, Singh M

Abstract
Minor salivary glands are ubiquitous in the oral cavity, and related diseases are often indolent and asymptomatic. We describe the unusual features of sclerosing polycystic adenosis, and its similarities to more sinister conditions of the minor salivary glands. Its importance is currently uncertain and research points to a pathogenesis that is neoplastic, which can create ambiguity. Sclerosing polycystic adenosis is a newly-discovered condition that merits further discussion and research to evaluate its full impact.

PMID: 30054028 [PubMed - as supplied by publisher]

Acinic cell carcinoma of the parotid gland in pregnancy: an approach to cancer in pregnancy.

Fetched: July 27th, 2018, 5:00am GMT

Acinic cell carcinoma of the parotid gland in pregnancy: an approach to cancer in pregnancy.

BMJ Case Rep. 2018 Jul 24;2018:

Authors: Cellich PP, Nayyar R, Wong E

Abstract
A 27-year-old woman presented with an enlarging painless right preauricular mass at 28 weeks' pregnant. The mass had been stable for more than 10 years, but showed rapid growth during pregnancy. Imaging and biopsy were consistent with parotid gland malignancy, with surgical resection undertaken at 33+4 weeks' gestation. Histopathology confirmed acinic cell carcinoma. Labour was induced without complication at 36+6 weeks' gestation and adjuvant radiotherapy commenced 2 weeks postpartum. At 9 months follow-up, both mother and baby were well, with no signs of disease recurrence. Rapid progression in pregnancy, of a previously stable salivary gland mass, is a common feature among reported cases and was also observed in the current case. This suggests an aetiological link between pregnancy and salivary gland tumour progression. We demonstrate successful management of a parotid gland malignancy in pregnancy and review guiding principles for cancer management in pregnancy.

PMID: 30042101 [PubMed - in process]

StatPearls

Fetched: July 20th, 2018, 5:00am GMT

StatPearls

Book. 2018 01

Authors:

PMID: 30020653

Gastric neuroendocrine carcinoma with positive staining for prostate cancer markers including prostate-specific antigen and alpha-methylacyl-CoA racemase.

Fetched: July 18th, 2018, 5:00am GMT

Gastric neuroendocrine carcinoma with positive staining for prostate cancer markers including prostate-specific antigen and alpha-methylacyl-CoA racemase.

Urol Case Rep. 2018 Sep;20:67-69

Authors: Hakozaki Y, Murata T, Yokoyama M, Matsushima H, Ogawa M, Masuda T, Hirai Y, Kume H

PMID: 30009133 [PubMed]

Overexpression of SOX11 and TFE3 in Solid-Pseudopapillary Neoplasms of the Pancreas.

Fetched: July 18th, 2018, 5:00am GMT

Overexpression of SOX11 and TFE3 in Solid-Pseudopapillary Neoplasms of the Pancreas.

Am J Clin Pathol. 2017 Dec 20;149(1):67-75

Authors: Harrison G, Hemmerich A, Guy C, Perkinson K, Fleming D, McCall S, Cardona D, Zhang X

PMID: 29272888 [PubMed - indexed for MEDLINE]

Close Margins and Adjuvant Radiotherapy in Acinic Cell Carcinoma of the Parotid Gland.

Fetched: July 8th, 2018, 5:00am GMT

Close Margins and Adjuvant Radiotherapy in Acinic Cell Carcinoma of the Parotid Gland.

JAMA Otolaryngol Head Neck Surg. 2018 Jul 05;:

Authors: Zenga J, Parikh AS, Emerick KS, Lin DT, Faquin WC, Deschler DG

Abstract
Importance: The precise indications and oncologic effects of adjuvant radiotherapy in acinic cell carcinoma of the parotid gland are not well known, particularly in patients with negative, but close (≤1 mm), margins without other high-risk histopathologic factors.
Objective: To evaluate the oncologic outcomes of patients with acinic cell carcinoma of the parotid gland and the results of adjuvant therapy for those with close (≤1-mm) margins.
Design, Setting, and Participants: In a retrospective case series with medical record review at a single academic tertiary referral center, patients treated surgically from January 2000 to December 2014 for acinic cell carcinoma of the parotid gland were identified from an institutional database. All data analysis was performed in September 2017.
Exposures: All patients underwent parotidectomy with or without adjuvant radiotherapy or chemoradiotherapy.
Main Outcomes and Measures: The primary end point was locoregional control. Secondary end points included recurrence patterns and survival.
Results: Forty-five patients were identified in this case series (23 [51%] female), with a mean (SD) age of 47.1 (19.5) years. The median follow-up in surviving patients was 56.7 months (range, 18.5-204 months). Four patients (9%) experienced recurrence (1 local and 3 distant) at a median of 67.3 months (range, 12.7-136 months) after surgery. Thirteen patients (29%) had at least one high-risk histopathologic factor (advanced T category, nodal disease, lymphovascular or perineural invasion, high-grade, or positive margins). The remaining 32 patients (71%) without these high-risk factors had significantly improved disease-free survival (hazard ratio, 0.08; 95% CI, 0.01-0.71). Of patients without high-risk factors, those with close (≤1-mm) margins were significantly more likely to receive adjuvant radiotherapy (10 [56%] vs 1 [7%]; difference, 49%; 95% CI, 16%-82%), although this was not associated with disease control. At a median follow-up of 64.3 months (range, 33-204 months) in the 18 patients with close (≤1-mm) margins without other high-risk factors (10 with adjuvant radiotherapy and 8 without adjuvant therapy), only 1 patient (who had received adjuvant radiotherapy) experienced a recurrence, at 136 months after surgery.
Conclusions and Relevance: Patients with acinic cell carcinoma of the parotid gland whose only histopathologic risk factor is a close (≤1 mm) but negative margin do not appear to benefit from adjuvant radiotherapy. Recurrent disease is rare but may occur many years after initial treatment, and patients with acinic cell carcinoma could benefit from lifelong clinical surveillance.

PMID: 29978180 [PubMed - as supplied by publisher]

Primary Hepatoid Carcinoma of the Pancreas: A Clinicopathological Study of 3 Cases With Review of Additional 31 Cases in the Literature.

Fetched: July 4th, 2018, 5:00am GMT

Primary Hepatoid Carcinoma of the Pancreas: A Clinicopathological Study of 3 Cases With Review of Additional 31 Cases in the Literature.

Int J Surg Pathol. 2018 Jun 01;:1066896918783468

Authors: Yang C, Sun L, Lai JZ, Zhou L, Liu Z, Xi Y, Tao Y, Dooley E, Cao D

PMID: 29961402 [PubMed - as supplied by publisher]

Microglandular adenosis of the breast: a deceptive and still misterious benign lesion.

Fetched: June 29th, 2018, 5:00am GMT

Microglandular adenosis of the breast: a deceptive and still misterious benign lesion.

Hum Pathol. 2018 Jun 24;:

Authors: Foschini MP, Eusebi V

Abstract
Microglandular adenosis of the breast (MA), a benign glandular proliferation, was originally described about 35years ago. The lesion, is constituted by small glands all of the same size. Glands are lined by one layer of cuboidal epithelial cells encircled by basal lamina without any evidence of interposed myoepithelial elements. Cells are positive for low weight keratins and S-100 protein and negative for ER, PR and HER 2. Since then, in the years, several malignant lesions all showing microglandular architecture have been regarded either as a precursor or an equivalent manifestation of MA. The latter has been associated to a large number of malignancies that include DCIS, LCIS, ademyoepithelioma, high grade basal like carcinoma, adenoid cystic carcinoma, matrix producing carcinoma, invasive duct carcinoma NOS, spindle cell carcinoma, not to mention acinic cell carcinoma. None of the above tumors were identical to MA. Differences mainly rested not only on the specific structure of the small glands but also on the cytological composition and immunohistochemical features of different lesions. Here a review of the features of MA together with the differential diagnosis with lesions showing microglandular structure is discussed. MA shows similarities with a lesion named microglandular hamartoma/adenosis (MH) of the nasal cavity. The relation of the two similar lesions is discussed.

PMID: 29949742 [PubMed - as supplied by publisher]

Prostatic Adenocarcinoma With Focal Pleomorphic Giant Cell Features: A Series of 30 Cases.

Fetched: June 28th, 2018, 5:00am GMT

Prostatic Adenocarcinoma With Focal Pleomorphic Giant Cell Features: A Series of 30 Cases.

Am J Surg Pathol. 2018 Jun 25;:

Authors: Alharbi AM, De Marzo AM, Hicks JL, Lotan TL, Epstein JI

PMID: 29944471 [PubMed - as supplied by publisher]

Preoperative Treatment With FOLFIRINOX and Successful Resection for a Patient With Mixed Acinar-Endocrine Carcinoma of the Pancreas.

Fetched: June 27th, 2018, 5:00am GMT

Preoperative Treatment With FOLFIRINOX and Successful Resection for a Patient With Mixed Acinar-Endocrine Carcinoma of the Pancreas.

Pancreas. 2017 Apr;46(4):e32-e34

Authors: Sugimoto M, Hines OJ, Dawson DW, Muthusamy VR, Reber HA, Donahue TR

PMID: 28291165 [PubMed - indexed for MEDLINE]

Permalink for 'Four-Year Survival of a Patient With Spinal Metastatic Acinic Cell Carcinoma After a Total En Bloc Spondylectomy and Reconstruction With a Frozen Tumor-Bearing Bone Graft.'

Four-Year Survival of a Patient With Spinal Metastatic Acinic Cell Carcinoma After a Total En Bloc Spondylectomy and Reconstruction With a Frozen Tumor-Bearing Bone Graft.

Fetched: June 20th, 2018, 5:00am GMT

Four-Year Survival of a Patient With Spinal Metastatic Acinic Cell Carcinoma After a Total En Bloc Spondylectomy and Reconstruction With a Frozen Tumor-Bearing Bone Graft.

Orthopedics. 2018 Jun 18;:1-4

Authors: Sangsin A, Murakami H, Shimizu T, Kato S, Tsuchiya H

Abstract
Acinic cell carcinoma metastasizing to the spine is extremely rare. The authors present a case of acinic cell carcinoma of the parotid gland with subsequent lung and spinal metastases, treated with en bloc spondylectomy. A 41-year-old man presented with a left parotid mass. After being diagnosed with acinic cell carcinoma, he underwent a total parotidectomy. Imaging studies revealed a metastatic osteoblastic lesion in the T4 vertebral body and multiple lung metastases. Total en bloc spondylectomy and reconstruction with a frozen tumor-bearing bone graft were performed to treat the T4 metastasis. Lung metastases were treated with periodic radiofrequency ablation. At the 48-month follow-up, there was no local recurrence of the lesions, and the lung metastases were controlled. The bone graft had fused with the adjacent vertebrae, and the patient had full neurological function and normal daily activities. This report indicates satisfactory long-term outcomes of total en bloc spondylectomy and reconstruction with frozen tumor-bearing bone graft in a patient with acinic cell carcinoma with spinal metastasis. It also emphasizes the benefits of radical resection of spinal metastasis even in cases with multiple organ metastases. [Orthopedics. 201x; xx(x):xx-xx.].

PMID: 29913031 [PubMed - as supplied by publisher]

Systemic therapy in non-conventional cancers of the larynx.

Fetched: June 20th, 2018, 5:00am GMT

Systemic therapy in non-conventional cancers of the larynx.

Oral Oncol. 2018 Jul;82:61-68

Authors: Tan E, Mody MD, Saba NF

Abstract
Laryngeal cancer (LC) remains a challenging disease to treat. The majority of LCs diagnosed worldwide are squamous cell carcinomas (SCC), and current treatment guidelines are designed to address conventional laryngeal SCC. However, several histologically rare tumor types can originate in the larynx. There is a lack of guidelines regarding the best therapeutic approaches to these tumors and their treatment is often modeled after their recommended management at non-laryngeal sites. Understanding the role for systemic therapy in these rare tumors is important, especially for patients with advanced disease or those who are not surgical candidates. We provide in this manuscript a detailed and comprehensive overview of systemic therapy considerations for the following histologic tumor types of the larynx: verrucous carcinoma (VC), HPV-related SCC, basaloid SCC (BSCC), lymphoepithelial carcinoma (LEC), adenosquamous carcinoma (ASC), typical and atypical carcinoid, small cell neuroendocrine carcinoma (SCNC), large cell neuroendocrine carcinoma (LCNC), NUT midline carcinomas (NUTMC), melanoma, adenoid cystic carcinoma, rhabdomyosarcoma (RMS), malignant fibrous histiocytoma (MFH), lymphoma, mucoepidermoid carcinoma (MEC), acinic cell carcinoma, and spindle cell carcinoma (SpCC).

PMID: 29909903 [PubMed - in process]

Outcomes and prognostic factors for parotid acinic cell Carcinoma: A National Cancer Database study of 2362 cases.

Fetched: June 20th, 2018, 5:00am GMT

Outcomes and prognostic factors for parotid acinic cell Carcinoma: A National Cancer Database study of 2362 cases.

Oral Oncol. 2018 Jul;82:53-60

Authors: Scherl C, Kato MG, Erkul E, Graboyes EM, Nguyen SA, Chi AC, Morgan PF, Day TA

Abstract
OBJECTIVES: To evaluate the demographics, clinical features, survival outcomes, and prognostic indicators of patients with acinic cell carcinoma (ACC) of the parotid gland with emphasis on the roles of grade, tumor size, and nodal status in survival.
MATERIALS AND METHODS: A retrospective analysis of cases diagnosed between 2004 and 2012 from the National Cancer Database was performed. Multivariable logistic regression was used to determine factors associated with survival.
RESULTS: 2362 cases were identified. Most patients were females (61.3%) and Caucasian (85.4%) with a median age of 54 years (range, 18-90 years). Most tumors were <3 cm in size (75.8%). Regional metastases and high-grade histology were rare (8.2%, 5.1%). All patients received surgery as primary treatment with 42.7% of patients receiving adjuvant radiation therapy or chemoradiotherapy. 5 year overall survival was 88.6%. On multivariable analysis, age >70 years (hazard ratio [HR]: 10.05, 95% confidence interval [CI]: 5.64-17.91), high-grade (HR: 5.30, 95% CI: 3.39-8.29), tumor size of 3 to 6 cm (HR: 1.53, 95% CI: 1.10-2.12), tumor size >6 cm (HR: 2.98, 95% CI: 1.681-5.289), pN2+ (HR: 3.14, 95% CI: 2.10-4.69), T4 (HR: 2.89, 95% CI: 1.74-4.80) were significant prognosticators.
CONCLUSION: Although patients with ACC generally are considered to have a favorable prognosis, an aggressive subgroup with poor outcomes was identified. This group is characterized by high-grade, advanced T classification, tumors larger than 3 cm, with regional metastases and age greater than 70 years. Histologic grade is a substantially stronger predictor of survival than T and N classifications.

PMID: 29909902 [PubMed - in process]

Duct- and Acinar-Derived Pancreatic Ductal Adenocarcinomas Show Distinct Tumor Progression and Marker Expression.

Fetched: June 15th, 2018, 5:00am GMT

Duct- and Acinar-Derived Pancreatic Ductal Adenocarcinomas Show Distinct Tumor Progression and Marker Expression.

Cell Rep. 2017 Oct 24;21(4):966-978

Authors: Ferreira RMM, Sancho R, Messal HA, Nye E, Spencer-Dene B, Stone RK, Stamp G, Rosewell I, Quaglia A, Behrens A

PMID: 29069604 [PubMed - indexed for MEDLINE]

Fibroblast-derived HGF drives acinar lung cancer cell polarization through integrin-dependent RhoA-ROCK1 inhibition.

Fetched: June 15th, 2018, 5:00am GMT

Fibroblast-derived HGF drives acinar lung cancer cell polarization through integrin-dependent RhoA-ROCK1 inhibition.

Cell Signal. 2017 Dec;40:91-98

Authors: Datta A, Sandilands E, Mostov KE, Bryant DM

PMID: 28888686 [PubMed - indexed for MEDLINE]

Aging dependent effect of nuclear tau.

Fetched: June 13th, 2018, 5:00am GMT

Aging dependent effect of nuclear tau.

Brain Res. 2017 Dec 15;1677:129-137

Authors: Gil L, Federico C, Pinedo F, Bruno F, Rebolledo AB, Montoya JJ, Olazabal IM, Ferrer I, Saccone S

PMID: 28974363 [PubMed - indexed for MEDLINE]

Bioengineered Submucosal Organoids for In Vitro Modeling of Colorectal Cancer.

Fetched: June 13th, 2018, 5:00am GMT

Bioengineered Submucosal Organoids for In Vitro Modeling of Colorectal Cancer.

Tissue Eng Part A. 2017 Oct;23(19-20):1026-1041

Authors: Devarasetty M, Skardal A, Cowdrick K, Marini F, Soker S

PMID: 28922975 [PubMed - indexed for MEDLINE]

Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases.

Fetched: June 13th, 2018, 5:00am GMT

Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases.

Histopathology. 2017 Oct;71(4):641-647

Authors: Samaratunga H, Delahunt B, Srigley JR, Yaxley J, Johannsen S, Coughlin G, Gianduzzo T, Kua B, Patterson I, Nacey JN, Egevad L

PMID: 28590015 [PubMed - indexed for MEDLINE]

Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate.

Fetched: June 11th, 2018, 5:00am GMT

Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate.

Hum Pathol. 2018 Jun 06;:

Authors: Xue W, Xin Z, Zhang Y, Jiang Z, Zhao L, Fan L, Wang Y, Xie S, Shangguan X, Zhu Y, Pan J, Liu Q, Huang Y, Dong B

PMID: 29885405 [PubMed - as supplied by publisher]

Synchronous Parotid (Mammary Analog) Secretory Carcinoma and Acinic Cell Carcinoma: Report of a Case.

Fetched: June 9th, 2018, 5:00am GMT

Synchronous Parotid (Mammary Analog) Secretory Carcinoma and Acinic Cell Carcinoma: Report of a Case.

Head Neck Pathol. 2018 Jun 06;:

Authors: Mossinelli C, Pigni C, Sovardi F, Occhini A, Preda L, Benazzo M, Morbini P, Pagella F

Abstract
Mammary analogue secretory carcinoma (MASC) is a recently described low-grade salivary gland malignancy with histologic, immunohistochemical and molecular similarities to secretory carcinoma of the breast, including a specific t(12;15)(p13;q25) resulting in an ETV6-NTRK3 gene fusion. Ultrasound and magnetic resonance imaging frequently document a macrocystic structure. The main differential diagnosis of secretory carcinoma is with low grade acinic cell carcinoma (AciCC). The two can be differentiated with immunohistochemical stains for S100, mammaglobin, carbonic anhydrase VI and DOG-1; the identification of the specific translocation can help to characterize non-typical cases. We report a unique case of synchronous MASC and AciCC presenting in a parotid gland and discuss the implications of the correct identification of the two tumors.

PMID: 29876739 [PubMed - as supplied by publisher]

Hepatoid Adenocarcinoma of Unknown Primary Masquerading as a Pancreatic Tumor.

Fetched: June 8th, 2018, 5:00am GMT

Hepatoid Adenocarcinoma of Unknown Primary Masquerading as a Pancreatic Tumor.

J Gastrointest Surg. 2017 Dec;21(12):2132-2134

Authors: Dogeas E, Peng L, Choti MA

PMID: 28681213 [PubMed - indexed for MEDLINE]

Clinical characteristics and prognosis of patients with lung adenosquamous carcinoma after surgical resection: results from two institutes.

Fetched: June 2nd, 2018, 5:00am GMT

Clinical characteristics and prognosis of patients with lung adenosquamous carcinoma after surgical resection: results from two institutes.

J Thorac Dis. 2018 Apr;10(4):2397-2402

Authors: Zhu L, Jiang L, Yang J, Gu W, He J

PMID: 29850145 [PubMed]

Accuracy of preoperative fine needle aspiration in diagnosis of malignant parotid tumors.

Fetched: June 1st, 2018, 5:00am GMT

Accuracy of preoperative fine needle aspiration in diagnosis of malignant parotid tumors.

Saudi Med J. 2017 Oct;38(10):1000-1006

Authors: Marzouki HZ, Altabsh MA, Albakrei MO, Al-Khatib TA, Merdad MA, Farsi NJ

PMID: 28917063 [PubMed - indexed for MEDLINE]

XAV939 inhibits the proliferation and migration of lung adenocarcinoma A549 cells through the WNT pathway.

Fetched: May 30th, 2018, 5:00am GMT

XAV939 inhibits the proliferation and migration of lung adenocarcinoma A549 cells through the WNT pathway.

Oncol Lett. 2018 Jun;15(6):8973-8982

Authors: Li C, Zheng X, Han Y, Lv Y, Lan F, Zhao J

PMID: 29805633 [PubMed]

Pulmonary adenocarcinoma with high-grade fetal adenocarcinoma component has a poor prognosis, comparable to that of micropapillary adenocarcinoma.

Fetched: May 24th, 2018, 5:00am GMT

Pulmonary adenocarcinoma with high-grade fetal adenocarcinoma component has a poor prognosis, comparable to that of micropapillary adenocarcinoma.

Mod Pathol. 2018 May 21;:

Authors: Suzuki M, Nakatani Y, Ito H, Narimatsu H, Yamada K, Yoshioka E, Washimi K, Okubo Y, Kawachi K, Miyagi Y, Yokose T

PMID: 29785018 [PubMed - as supplied by publisher]

[Acquired cystic kidney disease-associated renal cell carcinoma: a clinicopathologic study of three cases].

Fetched: May 24th, 2018, 5:00am GMT

[Acquired cystic kidney disease-associated renal cell carcinoma: a clinicopathologic study of three cases].

Zhonghua Bing Li Xue Za Zhi. 2018 May 08;47(5):366-371

Authors: Zhang W, Xu LL, Yu WJ, Wang Q, Jiang YX, Liu Y, Li YJ

PMID: 29783804 [PubMed - in process]

Phospho-valproic acid inhibits pancreatic cancer growth in mice: enhanced efficacy by its formulation in poly-(L)-lactic acid-poly(ethylene glycol) nanoparticles.

Fetched: May 24th, 2018, 5:00am GMT

Phospho-valproic acid inhibits pancreatic cancer growth in mice: enhanced efficacy by its formulation in poly-(L)-lactic acid-poly(ethylene glycol) nanoparticles.

Int J Oncol. 2017 Oct;51(4):1035-1044

Authors: Mattheolabakis G, Wang R, Rigas B, Mackenzie GG

PMID: 28849098 [PubMed - indexed for MEDLINE]

Molecular Diagnostics in the Neoplasms of the Pancreas, Liver, Gallbladder, and Extrahepatic Biliary Tract: 2018 Update.

Fetched: May 21st, 2018, 5:00am GMT

Molecular Diagnostics in the Neoplasms of the Pancreas, Liver, Gallbladder, and Extrahepatic Biliary Tract: 2018 Update.

Clin Lab Med. 2018 Jun;38(2):367-384

Authors: Zhang L, Bluth MH, Bhalla A

PMID: 29776636 [PubMed - in process]

Novel interleukin-33 and its soluble ST2 receptor as potential serum biomarkers in parotid gland tumors.

Fetched: May 17th, 2018, 5:00am GMT

Novel interleukin-33 and its soluble ST2 receptor as potential serum biomarkers in parotid gland tumors.

Exp Biol Med (Maywood). 2018 May;243(9):762-769

Authors: Pawel S, Maciej M, Maciej Z, Bogdan M, Monika AS

Abstract
An increasing number of patients with parotid gland tumors have been observed in recent years. The relationship between the immune system and tumor formation is thoroughly investigated. However, newly discovered molecules offer a new insight into the pathophysiology of malignancies. It would be ideal to find an easily determinable biomarker of tumor existence, its malignant potential or a biomarker suggesting the probability of disease recurrence. Our study is the first to examine serum concentrations of IL-33 and its sST2 receptor in patients with various types of parotid gland tumors. Serum IL33, sST2, IL-4 and IL-10 concentrations were determined in patients with benign and malignant parotid gland tumors (pleomorphic adenoma, Warthin's tumor, myoepithelioma and acinic cell carcinoma). We observed for the first time that serum IL-33 level was significantly elevated in patients with various types of parotid gland tumors and sST2 levels were significantly higher in pleomorphic adenoma and acinic cell carcinoma patients compared to the controls. Our results demonstrate for the first time that serum IL-33 and its sST2 receptor may be important factors in the pathology of parotid gland tumors. Although our results are promising, further investigations are required to detect if serum concentrations of those molecules may be a biomarker in parotid gland tumors. Impact statement Parotid gland tumors seem to be an increasingly important medical challenge, mostly due to a noticeable increase in the incidence. It would be crucial to find an easily determinable biomarker of tumor existence, its recurrence or malignant potential. We observed for the first time that serum IL-33 level was significantly elevated in patients with various types of parotid gland tumors and its sST2 receptor levels were significantly higher in pleomorphic adenoma and acinic cell carcinoma patients compared to the controls. We believe that our study helps to understand the biology of the tumors and a potential role of a relatively newly identified cytokine IL-33 in the pathophysiology of the parotid gland tumors.

PMID: 29763370 [PubMed - in process]

GRP78 haploinsufficiency suppresses acinar-to-ductal metaplasia, signaling, and mutant Kras-driven pancreatic tumorigenesis in mice.

Fetched: May 17th, 2018, 5:00am GMT

GRP78 haploinsufficiency suppresses acinar-to-ductal metaplasia, signaling, and mutant Kras-driven pancreatic tumorigenesis in mice.

Proc Natl Acad Sci U S A. 2017 05 16;114(20):E4020-E4029

Authors: Shen J, Ha DP, Zhu G, Rangel DF, Kobielak A, Gill PS, Groshen S, Dubeau L, Lee AS

PMID: 28461470 [PubMed - indexed for MEDLINE]

What is your diagnosis? Mandibular mass in a cat.

Fetched: May 16th, 2018, 5:00am GMT

What is your diagnosis? Mandibular mass in a cat.

Vet Clin Pathol. 2018 May 14;:

Authors: Newman AW, Asakawa MG, Stokol T

PMID: 29758098 [PubMed - as supplied by publisher]

The screening and electron microscopy observation of mammary analogue secretory carcinoma in Chinese.

Fetched: May 14th, 2018, 5:00am GMT

The screening and electron microscopy observation of mammary analogue secretory carcinoma in Chinese.

J Craniomaxillofac Surg. 2017 Oct 19;:

Authors: Zhong Y, Liu L, Qi B, Song X, Shen L, Li H

PMID: 29752049 [PubMed - as supplied by publisher]

Central Acinic Cell Carcinoma of the Mandible Simulating as Benign Odontogenic Lesion: A Case Report.

Fetched: May 13th, 2018, 5:00am GMT

Central Acinic Cell Carcinoma of the Mandible Simulating as Benign Odontogenic Lesion: A Case Report.

Iran J Med Sci. 2018 Mar;43(2):223-226

Authors: Bajpai M, Pardhe N, Chandolia B, Arora M

PMID: 29749993 [PubMed]

Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice.

Fetched: May 11th, 2018, 5:00am GMT

Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice.

Gastroenterology. 2018 04;154(5):1494-1508.e13

Authors: He P, Yang JW, Yang VW, Bialkowska AB

PMID: 29248441 [PubMed - indexed for MEDLINE]

Immunohistochemical Detection of Proliferative Marker Ki-67 in Benign and Malignant Salivary Gland Tumors.

Fetched: May 9th, 2018, 5:00am GMT

Immunohistochemical Detection of Proliferative Marker Ki-67 in Benign and Malignant Salivary Gland Tumors.

J Contemp Dent Pract. 2018 Apr 01;19(4):375-383

Authors: Bussari S, Ganvir SM, Sarode M, Jeergal PA, Deshmukh A, Srivastava H

Abstract
Introduction: Salivary gland tumors are the most histologically heterogeneous group of tumors with the greatest diversity of morphologic features among their cells and tissues. The present study was aimed at assessing the validity of Ki-67, a cell proliferation marker, as a prognostic factor in benign and malignant salivary gland tumors and to study whether it is related to age, sex, anatomical site, and size of the lesion in salivary gland tumors. Materials and methods: A retrospective study consisted of benign salivary gland tumors (BSGTs) (n = 15), malignant salivary gland tumors (n = 18), and normal salivary gland parenchyma (n = 15). Results: There was a significant difference of Ki-67 labeling index (LI, %) in normal salivary gland parenchyma, BSGTs, and malignant salivary gland tumors. The Ki-67 LI (%) in normal salivary gland parenchyma is negligible (0.27 ± 0.31%), whereas malignant salivary gland tumors showed very high Ki-67 LI (%) of 18.79 ± 18.06% compared with BSGTs being 0.76 ± 2.02%. There was a significant correlation statistically of mean ± standard deviation (SD) of Ki-67 LI (%) with the age of the patients being the maximum (32.68 ± 15.87%) in the 50 to 59 years age group, whereas sex, site of the lesion, and size of the lesion in salivary gland tumors had no significant correlation. Conclusion: The Ki-67 is a useful marker for assessing prolif-erative potential of tumors. Clinical significance: The Ki-67 LI% can be used as a reliable adjuvant diagnostic tool to differentiate between the subtypes and grading of certain malignant tumors, such as mucoepi-dermoid carcinoma (MEC), adenoid cystic carcinoma (AdCC), and acinic cell carcinoma (AcCC), which are usually difficult to diagnose on histopathological criteria alone. Keywords: Immunohistochemistry, Ki-67, Salivary gland neoplasms.

PMID: 29728539 [PubMed - in process]

Evidence Based Tailored Parotidectomy in Treating External Auditory Canal Carcinoma.

Fetched: August 17th, 2018, 5:00am GMT

Evidence Based Tailored Parotidectomy in Treating External Auditory Canal Carcinoma.

Sci Rep. 2018 Aug 14;8(1):12112

Authors: Lee JM, Joo JW, Kim SH, Choi JY, Moon IS

Abstract
Carcinoma of the external auditory canal (EAC) is a rare tumor and little information is available regarding parotid gland in surgically treating EAC carcinomas. This study aimed to investigate the mode of parotid involvement in EAC carcinoma through staging and histopathological analysis, and to establish surgical guidelines for the parotid gland management when there is no clinical evidence of parotid involvement. Sixty-five patients with EAC carcinoma who underwent temporal bone resection and any type of parotidectomy simultaneously were retrospectively reviewed. The rate of direct parotid invasion and parotid nodal involvement was analyzed according to the stage and histopathological findings. Among the 65 patients, 39 were confirmed to have squamous cell carcinoma (SCC) and 26 were confirmed to have adenoid cystic carcinoma (ACC). Direct parotid invasion occurred in 7 of 39 patients with SCC, only in the advanced stages, and in 15 of 26 patients with ACC, regardless of stage. Metastasis to the parotid node was noted in 6 patients with advanced-stage SCC, whereas no patient with ACC showed parotid nodal metastasis. For adequate tumor control with low risk of surgical complications, evidence based tailored parotidectomy should be applied. With no evidence of parotid involvement, an elective parotidectomy can be excluded in early SCC, whereas a total parotidectomy is recommended for advanced SCC. In ACC, basal resection of the parotid gland rather than a superficial or total parotidectomy should be performed at all disease stages.

PMID: 30108249 [PubMed - in process]

Liver metastasis from adenoid cystic carcinoma: imaging and histologic features.

Fetched: August 17th, 2018, 5:00am GMT

Liver metastasis from adenoid cystic carcinoma: imaging and histologic features.

Curr Probl Cancer. 2018 Jul 22;:

Authors: Picchia S, Riddell A, Terlizzo M, Bali MA

Abstract
Adenoid cystic carcinoma is a rare tumour. The reported incidence of isolated metastases to the liver is rare but possible and it seems to be more likely in case of perineural invasion.

PMID: 30107895 [PubMed - as supplied by publisher]

Impact of tumour profiling on clinical trials in salivary gland cancer.

Fetched: August 15th, 2018, 5:00am GMT

Impact of tumour profiling on clinical trials in salivary gland cancer.

Clin Otolaryngol. 2018 Aug 13;:

Authors: Rack S, Rahman R, Carter L, McKay C, Metcalf R

Abstract
Salivary gland cancer is a rare disease comprising multiple biologically diverse disease entities. Clinical trials have had relatively less impact on clinical practice in comparison with other cancer types. Here we describe clinical trials recruiting in salivary gland cancer and 'basket studies' incorporating molecular analysis using next generation sequencing (NGS) to stratify patients for molecularly targeted therapies. A systematic review of clinicaltrials. gov, PUBMED and ASCO, ESMO and AACR meeting abstracts was performed to identify clinical trials recruiting either salivary gland cancer cohorts or 'basket studies' which would be suitable for salivary gland cancer patients. Three of twenty trials recruiting salivary gland cancer patients were in the adjuvant setting. Of the remaining trials, 9/17 included molecular stratification for matched therapy. These included 3 large basket studies of matched therapy in molecular sub-groups (MATCH, TAPUR, and CAPTUR). Next generation sequencing (NGS) has utility to identify potentially actionable genetic alterations in salivary gland cancer and basket studies will identify signals of activity in these rare sub-groups and will generate novel biological hypotheses. However, to fully understand the functional significance of the molecular alterations within the context of salivary gland cancer, further laboratory and translational studies are required. This article is protected by copyright. All rights reserved.

PMID: 30102009 [PubMed - as supplied by publisher]

Permalink for 'Pure small-cell carcinoma of the prostate presenting with increasing prostate-specific antigen levels: A case report and review of the literature.'

Pure small-cell carcinoma of the prostate presenting with increasing prostate-specific antigen levels: A case report and review of the literature.

Fetched: August 15th, 2018, 5:00am GMT

Pure small-cell carcinoma of the prostate presenting with increasing prostate-specific antigen levels: A case report and review of the literature.

Mol Clin Oncol. 2018 Aug;9(2):197-200

Authors: Hu J, He T, Jin L, Li Y, Zhao Y, Li W, Wei B, Mao XM, Lai YQ, Ni LC

Abstract
The incidence of prostatic cancer (PCa) has increased significantly, and the measurement of prostate-specific antigen (PSA) is an effective screening tool for its diagnosis. PCa includes a number of specific clinicopathological types, including squamous cell, urothelial, adenoid cystic and small-cell carcinoma, among which small-cell carcinoma of the prostate (SCCP) is extremely rare, accounting for <0.5% of all PCa cases. SCCP is very aggressive and the majority of the cases have a poor prognosis, with a mean survival of ~5 months; it also exhibits specific clinicopathological characteristics and may be divided into two subtypes, namely pure and mixed SCCP. According to the previous literature on PubMed, pure SCCP is not associated with an increase in serum PSA levels. However, the rare case presented herein exhibited an increasingly abnormal serum PSA level. The patient was aged 66 years and had a PSA level of 56.78 ng/ml (normal, <4 ng/ml); he was diagnosed with pure SCCP, underwent radical prostatectomy and has remained disease-free during the follow-up. Similar cases previously published on PubMed were also reviewed, and considerations of survival status and treatment options were analyzed.

PMID: 30101021 [PubMed]

Comprehensive and in-depth analysis of microRNA and mRNA expression profile in salivary adenoid cystic carcinoma.

Fetched: August 14th, 2018, 5:00am GMT

Comprehensive and in-depth analysis of microRNA and mRNA expression profile in salivary adenoid cystic carcinoma.

Gene. 2018 Aug 08;:

Authors: Han N, Lu H, Zhang Z, Ruan M, Yang W, Zhang C

Abstract
OBJECTIVES: To conduct an integrated analysis of microRNA and mRNA expression profile and further discover vital molecules to uncover novel pathogenic mechanisms in salivary adenoid cystic carcinoma (SACC).
MATERIALS AND METHODS: MicroRNA and mRNA expression profiles were obtained from six paired primary SACC tumors and corresponding adjacent normal glands using high-throughput next-generation sequencing technology followed by an overall integrated bioinformatics analysis and subsequently molecular biology techniques validation.
RESULTS: Compared with adjacent noncancerous normal gland, 2107 significant differentially expressed mRNA were determined in SACC. Gene ontology and KEGG pathway analysis suggested that the differentially expressed genes were relevant to many significant biological implications. Venn diagram analysis of differentially expressed genes in different group identified 29 differentially expressed overlapping mRNA 40 differentially expressed microRNAs were also identified in SACC. Furthermore, integrated analysis of microRNA and mRNA expression profiles recognized a core microRNA-mRNA regulatory network and unmasked many novel genes including SCUBE3, CA6, hsa-miR-885-5p and other molecules which may play an essential role in the carcinogenesis of SACC. Also, QPCR and immunohistochemistry results reveal the high expression and distribution of SCUBE3 in SACC and dual luciferase reporter assay also preliminarily validated that SCUBE3 was a target of hsa-miR-885-5p.
CONCLUSION: Contemporary microRNA/mRNA analysis have uncovered many mRNAs and microRNAs worthy further exploration in SACC. These are bound to help us shed light on the overall genetic background of SACC and further elucidate the potential molecular mechanism of SACC.

PMID: 30098429 [PubMed - as supplied by publisher]

Permalink for 'A new approach to left sleeve pneumonectomy: complete VATS left pneumonectomy followed by right thoracotomy for carinal resection and reconstruction.'

A new approach to left sleeve pneumonectomy: complete VATS left pneumonectomy followed by right thoracotomy for carinal resection and reconstruction.

Fetched: August 14th, 2018, 5:00am GMT

A new approach to left sleeve pneumonectomy: complete VATS left pneumonectomy followed by right thoracotomy for carinal resection and reconstruction.

Surg Case Rep. 2018 Aug 10;4(1):91

Authors: Fujino T, Tanahashi M, Yukiue H, Suzuki E, Yoshii N, Shitara M, Kaminuma Y, Niwa H

Abstract
BACKGROUND: Left sleeve pneumonectomy is a challenging operation that requires individualized approaches. Here, we present a new minimally invasive combined thoracoscopic approach.
CASE PRESENTATION: A 61-year-old woman was diagnosed with tracheobronchial adenoid cystic carcinoma. The tumor originated from the left main stem bronchus, and tumor with carinal involvement was observed. We judged that complete resection would be possible via left sleeve pneumonectomy. However, because tumor involvement with the esophagus and descending aorta was suspected, evaluation of resectability in advance was necessary. After confirmation via examination thoracoscopy of no involvement with the surrounding organs, complete VATS left pneumonectomy was performed and followed by right thoracotomy for carinal resection and reconstruction.
CONCLUSIONS: When thoracoscopic surgery becomes mainstream, this minimally invasive combined thoracoscopic approach might be an optimal option for patients who require left sleeve pneumonectomy.

PMID: 30097740 [PubMed]

Permalink for 'Primary cutaneous adenoid cystic carcinoma mimicking dermal cylindroma: histology of the complete surgical excision as the key to diagnosis.'

Primary cutaneous adenoid cystic carcinoma mimicking dermal cylindroma: histology of the complete surgical excision as the key to diagnosis.

Fetched: August 12th, 2018, 5:00am GMT

Primary cutaneous adenoid cystic carcinoma mimicking dermal cylindroma: histology of the complete surgical excision as the key to diagnosis.

J Dtsch Dermatol Ges. 2018 Aug;16(8):1016-1018

Authors: Rütten A, Hegenbarth W, Kohl PK, Hillen U, Redler S

PMID: 30094921 [PubMed - in process]

Permalink for 'Tracheal segmental resection for tracheal cancer: comparison of cervical collar incision with median sternotomy and posterolateral incision.'

Tracheal segmental resection for tracheal cancer: comparison of cervical collar incision with median sternotomy and posterolateral incision.

Fetched: August 12th, 2018, 5:00am GMT

Tracheal segmental resection for tracheal cancer: comparison of cervical collar incision with median sternotomy and posterolateral incision.

J Surg Case Rep. 2018 Aug;2018(8):rjy201

Authors: Takanashi Y, Matsuura S, Neyatani H, Funai K

Abstract
We compare two surgical approaches for segmental tracheal resection for tracheal cancer: cervical collar incision with median sternotomy and right posterolateral incision. In case one, a 46-year-old woman presented with adenoid cystic carcinoma, measuring 4.5 cm longitudinally, located at the junction of the cervical and mediastinal trachea. Cervical collar incision with median sternotomy provided a good exposure of the entire trachea. Although a relatively long tracheal resection (5.0 cm) was required, sufficient mobilization of the entire trachea facilitated low-tension anastomosis. In case 2, a 39-year-old man presented with squamous cell carcinoma, measuring 1.8 cm longitudinally, located at the lower trachea 1.8 cm from the carina to the proximal side. Right posterolateral incision provided a good exposure of the lower trachea. Although the required tracheal resection was relatively short (3.0 cm), the anastomotic tension was high. The high anastomotic tension was likely attributed to the limited mobilization of the proximal trachea.

PMID: 30093998 [PubMed]

Restoring a Partial Maxillectomy Patient by an Implant-Supported Obturator on Two Implants: A Case Report.

Fetched: August 12th, 2018, 5:00am GMT

Restoring a Partial Maxillectomy Patient by an Implant-Supported Obturator on Two Implants: A Case Report.

J Dent (Tehran). 2018 May;15(3):187-192

Authors: Beyabanaki E, Alikhasi M

Abstract
This article describes the prosthetic treatment of a patient suffering from a hemimaxillary defect after surgical resection of an adenoid cystic carcinoma (ACC) in the palate. The patient had also received therapeutic irradiation. One year after radiotherapy, three implants were placed in the remaining maxillary bone without any bone augmentation. One of the implants failed during the osseointegration period. The implant replacing the failed one also failed during prosthetic procedures. The patient was unwilling to undergo another surgical episode, and the final prosthesis was completed on the two remaining implants.

PMID: 30090119 [PubMed]

Submandibular gland cancer: Specific features and treatment considerations.

Fetched: August 12th, 2018, 5:00am GMT

Submandibular gland cancer: Specific features and treatment considerations.

Head Neck. 2018 Jan;40(1):154-162

Authors: Aro K, Tarkkanen J, Saat R, Saarilahti K, Mäkitie A, Atula T

Abstract
BACKGROUND: In the absence of unified treatment protocol, we evaluated the management and outcomes of submandibular gland cancers in an unselected patient series.
METHODS: We included all patients with resected submandibular gland cancer treated at the Helsinki University Hospital from 2000 to 2010 with a 5-year minimum follow-up.
RESULTS: Twenty-five patients with cancer represented 30% of submandibular gland neoplasms, and most were adenoid cystic carcinomas (ACCs; 56%). At presentation, 3 patients showed clinical signs of probable malignancy. Of 22 neck dissection specimens, 5 patients (20%) had metastases with an occult metastasis rate of 4%. Cancer recurred in 11 patients (44%), of which 7 (28%) were only at a distant site. The 5-year disease-specific survival (DSS) and overall survival (OS) rates were 76%, and disease-free survival (DFS) was 68%.
CONCLUSION: Most tumors were ACCs differing from the histological pattern of parotid gland cancers. Occult metastases were rare. The rarity of submandibular gland cancer, its variable histological pattern, and varying biological behavior warrant centralized management.

PMID: 29083518 [PubMed - indexed for MEDLINE]

MicroRNAs expression pattern related to mast cell activation and angiogenesis in paraffin-embedded salivary gland tumors.

Fetched: August 9th, 2018, 5:00am GMT

MicroRNAs expression pattern related to mast cell activation and angiogenesis in paraffin-embedded salivary gland tumors.

Pathol Res Pract. 2017 Dec;213(12):1470-1476

Authors: Santos PRB, Coutinho-Camillo CM, Soares FA, Freitas VS, Vilas-Bôas DS, Xavier FCA, Rocha CAG, de Araújo IB, Dos Santos JN

Abstract
The aim of this study was evaluate the expression profile of microRNAs related to mast cells activation and angiogenesis in salivary glands tumors.
METHOD: We have analyzed the expression of miR-9, miR-16, miR-17, miR-132, miR-195 and miR-221 by real-time RT-PCR, in 11 adenoid cystic carcinomas, 9 mucoepidermoid carcinomas and 11 pleomorphic adenomas. Immunohistochemical investigation was performed to detect mast cells tryptase and CD-34 for microvessels biomarkers. miR-16, miR-17, miR-132, miR-195 and miR-221 showed a decreased expression, whereas miR-9 showed an increased expression in most cases compared to normal tissues. However, in all tumors studied only miR-9 showed a statistical significant negative correlation with microvessel density (p=0.001). It was observed a higher density of mast cells in mucoepidermoid carcinomas (10.55 cells/mm2) when compared to adenoid cystic carcinomas (6.27 cells/mm2) and between mucoepidermoid carcinomas and pleomorphic adenomas (5.97células/mm2). miR-17, miR-132, miR-195 and miR-221 seem to play an important role as tumor suppressor in salivary gland tumors. In addition, the significant correlation between mast cell and microvessel density contributes to the growth and pathogenesis of these tumors and they may become strong therapeutic targets in the future.

PMID: 29108921 [PubMed - indexed for MEDLINE]

Permalink for 'Strong SOX10 expression in HPV-related multiphenotypic sinonasal carcinoma: report of six new cases validated by high-risk HPV mRNA in situ hybridization test.'

Strong SOX10 expression in HPV-related multiphenotypic sinonasal carcinoma: report of six new cases validated by high-risk HPV mRNA in situ hybridization test.

Fetched: August 4th, 2018, 5:00am GMT

Strong SOX10 expression in HPV-related multiphenotypic sinonasal carcinoma: report of six new cases validated by high-risk HPV mRNA in situ hybridization test.

Hum Pathol. 2018 Jul 30;:

Authors: Hsieh MS, Lee YH, Jin YT, Huang WC

Abstract
HPV-related multiphenotypic sinonasal carcinoma (HMSC) is associated with high-risk human papillomavirus (HR-HPV) infection. Using HR-HPV mRNA in situ hybridization (ISH), we reported six new HMSC cases and compared their histopathology with that of sinonasal adenoid cystic carcinoma (ACC). Using p16 immunohistochemistry (IHC) and HR-HPV ISH, we retrospectively identified six HMSC cases. All HMSC cases were positive for HR-HPV mRNA ISH and p16 IHC. Two HMSC cases had overlying atypical squamous epithelium and one also had invasive squamous cell carcinoma (SCC). All HMSC were SOX10-positive whereas the overlying atypical squamous epithelium and the SCC were SOX10-negative. One atypical HMSC-like case was also identified which was positive for HR-HPV mRNA ISH, HR-HPV DNA ISH, SOX10 IHC, but negative for p16 IHC. This study showed that HR-HPV mRNA ISH was a useful tool to diagnose HMSC and had stronger signals than HR-HPV DNA ISH. HR-HPV E6/E7 mRNA could be identified in the overlying atypical squamous epithelium as well as the invasive SCC. A combination of p16 and SOX10 IHC will be a useful screening panel for HMSC followed by confirmatory HR-HPV mRNA ISH test.

PMID: 30071233 [PubMed - as supplied by publisher]

Long-term Outcomes of Globe-Preserving Surgery with Proton Beam Radiation for Adenoid Cystic Carcinoma of the Lacrimal Gland.

Fetched: August 4th, 2018, 5:00am GMT

Long-term Outcomes of Globe-Preserving Surgery with Proton Beam Radiation for Adenoid Cystic Carcinoma of the Lacrimal Gland.

Am J Ophthalmol. 2018 Jul 30;:

Authors: Wolkow N, Jakobiec FA, Lee H, Sutula FC

Abstract
PURPOSE: To describe outcomes of globe-preserving surgery combined with high dose proton beam radiation (PBR) in treating primary adenoid cystic carcinoma (ACC) of the lacrimal gland.
DESIGN: Retrospective case series.
METHODS: Twenty-nine patients with primary ACC of the lacrimal gland were identified in the records of a single institution between 1990 and 2017. Patients with non-orbital primary tumor origins or with inadequate follow-ups were excluded. Eighteen patients met inclusion criteria. Clinical data, imaging studies, histopathology, treatment modality, local recurrences, visual outcomes, metastases and survivals were assessed. Disease-free survivals for the current patients were measured and compared to those of other studies.
RESULTS: The eighteen patients (14 females, 4 males) were followed for a median of 12.9 years (range 0.6 to 22.3 years) post treatment completion. Their median age was 40 years. Four were children (median age 12 years). All were treated with globe-preserving tumor resection and radiation (median dose of 72 Cobalt Grey Equivalents). Three adult patients died from metastatic disease (median of 4.2 years after treatment). Four had local recurrences. Useful vision (20/40 or better) was retained for a median 3 years (range 1 to 12.9 years). Radiation morbidity included brain injury, retinopathy, optic neuropathy, keratopathy and cataract. Overall and disease-free survivals were significantly better compared to historical treatments, but did not differ statistically from other modern approaches.
CONCLUSIONS: Globe-preserving surgery with PBR, although imperfect, has a favorable long-term survival compared to other modern modalities with a variable period of useful vision.

PMID: 30071211 [PubMed - as supplied by publisher]

Permalink for 'MicroRNA dysregulation in adenoid cystic carcinoma of the salivary gland in relation to prognosis and gene fusion status: a cohort study.'

MicroRNA dysregulation in adenoid cystic carcinoma of the salivary gland in relation to prognosis and gene fusion status: a cohort study.

Fetched: August 4th, 2018, 5:00am GMT

MicroRNA dysregulation in adenoid cystic carcinoma of the salivary gland in relation to prognosis and gene fusion status: a cohort study.

Virchows Arch. 2018 Aug 01;:

Authors: Andreasen S, Tan Q, Agander TK, Hansen TVO, Steiner P, Bjørndal K, Høgdall E, Larsen SR, Erentaite D, Olsen CH, Ulhøi BP, Heegaard S, Wessel I, Homøe P

Abstract
Adenoid cystic carcinoma (ACC) is among the most frequent malignancies of the salivary gland, and is notorious for its prolonged clinical course characterized by frequent recurrences often years after initial treatment. No molecular marker has been shown to have independent prognostic value in ACC, including characteristic gene fusions involving MYB, MYBL1, and NFIB. MicroRNA has been shown to be associated with clinical outcome in numerous malignancies, including one study of ACC, warranting further validation of this class of markers in this disease. Here, we investigate the prognostic value of microRNA in two ACC cohorts: a training cohort (n = 64) and a validation cohort (n = 120) with microarray and qPCR. In the training cohort, multivariate analysis of microarray data found high expression of hsa-miR-6835-3p to be associated with reduced recurrence-free survival (RFS) (p = 0.016). Measuring the highest ranking microRNAs identified in survival analysis in the same cohort, qPCR identified high expression of hsa-miR-4676 to be associated with reduced overall survival (OS) and high expression of hsa-mir-1180 to be associated with improved RFS. This was not confirmed in the validation cohort, in which qPCR identified high expression of hsa-mir-21, hsa-mir-181a-2, and hsa-mir-152 to be associated with reduced OS and high expression of hsa-miR-374c to be associated with improved RFS. Interestingly, two distinct subsets of ACC separated in microRNA expression irrespective of gene fusion status, but without significant difference in outcome. Collectively, qPCR identified several microRNAs associated with OS and RFS, and different subsets of ACC separated according to microRNA expression, suggestive of ACC being a heterogeneous group of malignancies in its microRNA profile.

PMID: 30069755 [PubMed - as supplied by publisher]

Rare breast metastasis from adenoid cystic carcinoma of the submandibular gland.

Fetched: August 4th, 2018, 5:00am GMT

Rare breast metastasis from adenoid cystic carcinoma of the submandibular gland.

BMJ Case Rep. 2018 Aug 01;2018:

Authors: Krucoff KB, Shammas RL, Stoecker M, Tolnitch LA

Abstract
Adenoid cystic carcinomas (ACCs) are rare malignant neoplasms of exocrine glands, most commonly found in salivary glands. This report describes a 67-year-old woman with metastatic ACC to the breast, only the third reported case of its kind. The salivary gland ACC was first diagnosed 5 years prior. Routine mammogram identified a Breast Imaging and Reporting Systems (BIRADS) 4 lesion. Core breast biopsy demonstrated findings consistent with metastatic ACC to the breast. The patient ultimately underwent local excision but suffered a recurrence of disease less than 2 months later despite chemotherapy. She passed away 15 months after excision due to complications associated with a small bowel obstruction and decompensated respiratory status from pulmonary metastases. While metastatic salivary ACC to the breast is rare, it is important to be able to distinguish metastatic salivary ACC to the breast from primary ACC of the breast as the treatment considerations for the two disease processes differ significantly.

PMID: 30068574 [PubMed - in process]

Permalink for 'Three-year results after radiotherapy for locally advanced sinonasal adenoid cystic carcinoma, using highly conformational radiotherapy techniques proton therapy and/or Tomotherapy.'

Three-year results after radiotherapy for locally advanced sinonasal adenoid cystic carcinoma, using highly conformational radiotherapy techniques proton therapy and/or Tomotherapy.

Fetched: August 3rd, 2018, 5:00am GMT

Three-year results after radiotherapy for locally advanced sinonasal adenoid cystic carcinoma, using highly conformational radiotherapy techniques proton therapy and/or Tomotherapy.

Cancer Radiother. 2018 Jul 28;:

Authors: Dautruche A, Bolle S, Feuvret L, Le Tourneau C, Jouffroy T, Goudjil F, Zefkili S, Nauraye C, Rodriguez J, Herman P, Calugaru V

Abstract
PURPOSE: We report the patient outcomes of a treatment combining proton therapy and Tomotherapy in sinonasal adenoid cystic carcinoma involving skull base.
MATERIALS AND METHODS: We included patients treated at Curie Institute, Paris, France, between March 2010 and February 2014 for an advanced adenoid cystic carcinoma involving skull base. Patients received Tomotherapy, proton therapy or both. We evaluated treatment toxicity (according to CTCAE V4), local control, distant metastasis-free survival and overall survival.
RESULTS: Thirteen patients were included, with a median follow-up of 34 months. Radiation therapy followed surgery for 77% of the patients and margins were positive in all those cases. Median dose was 73.8Gy. Local control, distant metastasis-free survival and overall survival at 3 years were respectively 60%, 48% and 60%. One-sided grade 3 hearing impairment occurred in 46% of the patients.
CONCLUSION: Combining high-dose proton therapy and Tomotherapy is effective and has moderate toxicity in the treatment of T4 sinonasal adenoid cystic carcinoma involving skull base.

PMID: 30064829 [PubMed - as supplied by publisher]

Mutational landscape and clonal diversity of pulmonary adenoid cystic carcinoma.

Fetched: August 3rd, 2018, 5:00am GMT

Mutational landscape and clonal diversity of pulmonary adenoid cystic carcinoma.

Cancer Biol Ther. 2018 Aug 01;:1-6

Authors: Li M, Zhao BR, Liu SQ, An J, Deng PB, Han-Zhang H, Ye JY, Mao XR, Chuai SK, Hu CP

Abstract
Pulmonary adenoid cystic carcinoma is a rare and indolent lung malignancy, characterized by a protracted but unpredictable growth behavior. Currently, the treatment of PACC relies on surgery and local radiotherapy. However, treatment options for advanced PACC patients are limited. A larger number of studies demonstrated that advanced PACC patients obtained limited benefit from chemotherapy. Moreover, only a few case reports revealed PACC patients were candidates for target therapy. Therefore, there is an urgent need to develop novel therapies. Due to its rareness, its mutational landscape remains largely elusive. In this study, we performed capture-based ultra-deep sequencing on multiregional surgical specimens obtained from 8 PACC patients using a panel consisting of 295 cancer-related genes. Our data revealed distinctive mutational spectrum of PACC, which differed from non-small cell lung cancer and adenoid cystic carcinomas originated from other anatomical sites. PACC, lacking mutations in a majority of non-small cell lung cancer driver genes, has frequent mutations in genes participating in chromatin remodeling and NOTCH signaling pathway. We also elucidated spatial intra-tumoral heterogeneity, which varied among cases. Most mutations in chromatin remodelers were subclonal. Collectively, our findings elucidated molecular signature associated with PACC and highlighted the potential for epigenetic therapy in this disease.

PMID: 30067437 [PubMed - as supplied by publisher]

First-in-human study of LY3039478, an Oral Notch signaling inhibitor in advanced or metastatic cancer.

Fetched: August 1st, 2018, 5:00am GMT

First-in-human study of LY3039478, an Oral Notch signaling inhibitor in advanced or metastatic cancer.

Ann Oncol. 2018 Jul 28;:

Authors: Massard C, Azaro A, Soria JC, Lassen U, Le Tourneau C, Sarker D, Smith C, Ohnmacht U, Oakley G, Patel BKR, Yuen ESM, Benhadji KA, Rodon J

Abstract
Background: Deregulated Notch signaling due to mutation or overexpression of ligands and/or receptors is implicated in various human malignancies. Gamma-secretase inhibitors inhibit Notch signaling by preventing cleavage of transmembrane domain of Notch protein. LY3039478 is a novel, potent Notch inhibitor decreases Notch signaling and its downstream biologic effects. In this first-in-human study, we report the safety, pharmacokinetic (PK) profile, pharmacodynamic effects, and antitumor activity of LY3039478 in patients with advanced or metastatic cancer.
Methods: This phase I, open-label, multicenter, nonrandomized, and dose-escalation phase study determined and confirmed the recommended phase II dose of LY3039478 (oral dose: 2.5-100 mg, TIW on a 28-day cycle). The primary objectives are to determine (part A) and confirm (part B) a recommended phase II dose that may be safely administered to patients with advanced or metastatic cancer, and secondary objectives include evaluation of safety, tolerability, PK parameters, and preliminary antitumor activity of LY3039478.
Results: A total of 110 patients were treated with LY3039478 monotherapy between 31 October 2012 and 15 July 2016. Dose-limiting toxicities were thrombocytopenia, colitis and nausea. Most adverse events were gastrointestinal. The recommended phase II dose was 50 mg TIW, because of its better tolerability compared to 75 mg. The pharmacokinetics of LY3039478 appeared dose proportional. Pharmacodynamic data indicate an approximately 80% inhibition of plasma Aβ, and >50% inhibition of Notch-regulated genes hairy and enhancer of split-1, cyclin D1 and Notch-regulated ankyrin repeat at 45-to 100-mg dose. Clinical activity (tumor necrosis, metabolic response or tumor shrinkage) was observed in patients with breast cancer, leiomyosarcoma, and adenoid cystic carcinoma.
Conclusion: Potent inhibition of Notch signaling by LY3039478 was well tolerated at doses associated with target engagement, and demonstrated evidence of clinical activity in heavily pretreated patients. Further investigation with LY3039478 as monotherapy and in combination with targeted agent or chemotherapy is ongoing.
Clinicaltrials.gov ID: NCT01695005.

PMID: 30060061 [PubMed - as supplied by publisher]

Sclerosing polycystic adenosis of the oral cavity.

Fetched: July 30th, 2018, 5:00am GMT

Sclerosing polycystic adenosis of the oral cavity.

Br J Oral Maxillofac Surg. 2018 Jul 24;:

Authors: Mumtaz S, Ali A, Singh M

PMID: 30054028 [PubMed - as supplied by publisher]

1 2 3 ... 58

Rare Cancer News & Clinical Trials

Feeds

Unread items (100)

Posted: August 12th, 2018, 8:16pm GMT

Posted: June 20th, 2018, 11:23pm GMT

Posted: April 27th, 2018, 4:09pm GMT

Posted: February 6th, 2018, 5:14pm GMT

Fetched: August 17th, 2018, 5:00am GMT

Fetched: August 15th, 2018, 5:00am GMT

Fetched: August 10th, 2018, 5:00am GMT

Fetched: August 9th, 2018, 5:00am GMT

Fetched: August 9th, 2018, 5:00am GMT

Fetched: August 7th, 2018, 5:00am GMT

Fetched: July 20th, 2018, 5:00am GMT

Fetched: July 18th, 2018, 5:00am GMT

Fetched: July 18th, 2018, 5:00am GMT

Fetched: July 4th, 2018, 5:00am GMT

Fetched: June 28th, 2018, 5:00am GMT

Fetched: June 27th, 2018, 5:00am GMT

Fetched: June 15th, 2018, 5:00am GMT

Fetched: June 15th, 2018, 5:00am GMT

Fetched: June 13th, 2018, 5:00am GMT

Fetched: June 13th, 2018, 5:00am GMT

Fetched: June 13th, 2018, 5:00am GMT

Fetched: June 11th, 2018, 5:00am GMT

Fetched: June 8th, 2018, 5:00am GMT

Fetched: June 2nd, 2018, 5:00am GMT

Fetched: June 1st, 2018, 5:00am GMT

Fetched: May 31st, 2018, 5:00am GMT

Fetched: May 25th, 2018, 5:00am GMT

Fetched: May 25th, 2018, 5:00am GMT

Fetched: May 25th, 2018, 5:00am GMT

Fetched: May 21st, 2018, 5:00am GMT

Fetched: May 17th, 2018, 5:00am GMT

Fetched: May 14th, 2018, 5:00am GMT

Fetched: May 13th, 2018, 5:00am GMT

Fetched: May 11th, 2018, 5:00am GMT

Posted: August 1st, 2018, 2:00pm GMT

Posted: June 27th, 2018, 2:00pm GMT

Posted: June 20th, 2018, 11:23pm GMT

Posted: May 21st, 2018, 7:25am GMT

Posted: October 6th, 2016, 5:10pm GMT

Posted: June 19th, 2015, 9:41am GMT

Posted: February 17th, 2015, 12:29pm GMT

Fetched: August 17th, 2018, 5:00am GMT

Fetched: August 15th, 2018, 5:00am GMT

Fetched: August 10th, 2018, 5:00am GMT

Fetched: August 8th, 2018, 5:00am GMT

Fetched: August 6th, 2018, 5:00am GMT

Fetched: July 30th, 2018, 5:00am GMT

Fetched: July 27th, 2018, 5:00am GMT

Fetched: July 20th, 2018, 5:00am GMT

Fetched: July 18th, 2018, 5:00am GMT

Fetched: July 18th, 2018, 5:00am GMT

Fetched: July 8th, 2018, 5:00am GMT

Fetched: July 4th, 2018, 5:00am GMT

Fetched: June 29th, 2018, 5:00am GMT

Fetched: June 28th, 2018, 5:00am GMT

Fetched: June 27th, 2018, 5:00am GMT

Fetched: June 20th, 2018, 5:00am GMT

Fetched: June 20th, 2018, 5:00am GMT

Fetched: June 20th, 2018, 5:00am GMT

Fetched: June 15th, 2018, 5:00am GMT

Fetched: June 15th, 2018, 5:00am GMT

Fetched: June 13th, 2018, 5:00am GMT

Fetched: June 13th, 2018, 5:00am GMT

Fetched: June 13th, 2018, 5:00am GMT

Fetched: June 11th, 2018, 5:00am GMT

Fetched: June 9th, 2018, 5:00am GMT

Fetched: June 8th, 2018, 5:00am GMT

Fetched: June 2nd, 2018, 5:00am GMT

Fetched: June 1st, 2018, 5:00am GMT

Fetched: May 30th, 2018, 5:00am GMT

Fetched: May 24th, 2018, 5:00am GMT